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Squamous cell carcinoma of the head and neck (SCCHN) ranks sixth among cancers worldwide. 
Despite recent advances in the detection and therapy of SCCHN, the five-year survival rate 
remains low.  Human papillomavirus (HPV) has been detected in a new class of SCCHN that has 
emerged in younger patients without the common risk factors of alcohol and/or tobacco.  HPV-
positive and HPV-negative SCCHN have different clinical characteristics, leading some to 
classify them as distinct diseases.  High-risk HPVs have been implicated in a number of cancers 
including cervical, anogenital, and head and neck cancers.  Micro (mi) RNAs are a recently 
discovered class of endogenously encoded small RNAs that most commonly function as negative 
regulators of gene expression.  MiRNA expression profiles are often altered in cellular stress 
conditions, including cancers and viral infections.  We hypothesized that HPV disrupts cellular 
miRNA expression in HPV-positive SCCHN and contributes to the development of this cancer.   
MiRNA microarray analysis of HPV-positive and HPV-negative SCCHN cell lines 
revealed the dysregulation of several miRNAs, including the upregulation of miR-363 and 
downregulation of miR-181a, miR-218, and miR-29a.  Exogenous expression of the HPV-16 E6 
oncogene in normal primary human keratinocytes showed similar changes in the above miRNAs, 
implicating HPV E6 in this up/downregulation.  Tissues from SCCHN patients in the western 
Pennsylvania area showed an HPV-positivity rate of 59 percent.  HPV-positive SCCHN cases 
were seen only in the tonsil and base of tongue, and patients with HPV-positive SCCHN were 
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diagnosed on average nine years younger than those with HPV-negative SCCHN. Additionally, 
miR-363 was upregulated in HPV-16-positive SCCHN tissues compared to the HPV-negative 
SCCHN tissues. 
We utilized gene expression data and spectral counting proteomics to narrow the possible 
cellular targets of miR-363 in SCCHN.  As confirmed via luciferase assays, miR-363 targets 
MYO1B, a myosin protein involved in cell motility.  Functional assays showed that 
overexpression of miR-363 in HPV-negative SCCHN cells or siRNA knockdown of MYO1B in 
HPV-positive SCCHN cells independently reduced cell migration.  Furthermore, the addition of 
miR-363 to HPV-negative SCCHN cells also caused an increase in cell proliferation and colony 
formation.   
Based on our studies, we envision that high-level expression of the E6 oncogene in HPV-
positive SCCHN results in an increase in miR-363 levels.  Increased expression of miR-363 may 
then reduce MYO1B levels, thereby reducing the migratory ability of these cells.  Furthermore, 
high levels of miR-363 may also promote cellular proliferation and colony formation.  
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1.1 SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK 
Squamous cell carcinoma of the head and neck (SCCHN) arises in the mucosal linings of the 
larynx, nasal cavity, oral cavity, paranasal sinuses, pharynx, or oropharynx and ranks sixth 
among cancers worldwide (Kamangar et al., 2006).  In the United States, population-based 
studies estimate there will be 40,250 new cases of oral cavity and pharynx cancers and 12,360 
new cases of laryngeal cancers, resulting in 7,850 and 3,650 deaths in 2012, respectively (Siegel 
et al., 2012).  The majority of SCCHN patients are diagnosed with stage III or stage IV tumors, 
often involving regional lymph nodes (Jemal et al., 2010).  The SCCHN 5-year survival rate of 
~60 percent has not improved in the past ten years, indicating a great need for understanding the 
mechanisms of SCCHN pathogenesis (Howlader et al., 2011). 
Well-known risk factors for SCCHN include alcohol consumption and tobacco use (Blot 
et al., 1988), which over time induce mutations in essential genetic pathways that regulate the 
cell cycle.  Reactivation of telomerase is seen in up to 90 percent of SCCHN (McCaul et al., 
2002), the loss of 9p21, which encodes p16, is seen in 70-80 percent of SCCHN (Mao et al., 
1996; Reed et al., 1996), the cyclin D1 gene CCND1 located on chromosome 11q13 is amplified 
in up to 80 percent of SCCHN (Smeets et al., 2006), and mutations in the p53 tumor suppressor 
gene are seen in 60-80 percent of SCCHN (Balz et al., 2003; Poeta et al., 2007; van Houten et 
al., 2002).  Additionally, high expression of epidermal growth factor receptor (EGFR) is seen in 
90 percent of SCCHN cases (Grandis and Tweardy, 1993) and is associated with a poor 
prognosis (Rubin Grandis et al., 1998).   
There has been a decrease in the overall number of SCCHN cases in the past ten years, 
however there has been an increase in the cases of oropharyngeal SCCHN, where patients are 
being diagnosed at a younger age compared to the other SCCHN sites (Chaturvedi et al., 2008).  
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The increase in the subset of SCCHN arising in the oropharynx is due to infection with high-risk 
human papillomavirus (HPV), and often occurs in individuals without the risk factors of alcohol 
consumption or tobacco use, leading some to classify HPV-positive SCCHN as a distinct tumor 
entity (Vidal and Gillison, 2008).   
1.2 HUMAN PAPILLOMAVIRUS 
Papillomaviruses are members of the Papillomaviridae family of viruses and can infect a variety 
of animals including mammals and birds.  Human papillomaviruses (HPVs) are common wart-
causing viruses, with over 150 types identified to date (de Villiers et al., 2004).  HPVs are small 
double-stranded DNA, nonenveloped viruses that infect the basal lamina of skin and mucous 
membranes.  They contain a circular genome of approximately 8 kb, that can be divided into 
three major regions: early (coding for E1, E2, E4, E5, E6, and E7), late (coding for L1 and L2), 
and a long control region (LCR, non-coding) (Hebner and Laimins, 2006).  Due to their small 
genome size, HPVs do not encode most enzymes that are required for their replication.  
Therefore, the HPV life cycle depends upon the ability of the infected host cells to differentiate 
and proliferate.  HPV infects the basal layer of squamous epithelial cells, usually through 
abrasions or lesions in the skin or mucosa.  In basal cells, the HPV genome is maintained in low-
copy episomal form, and early genes are turned on.  The early HPV promoter activates 
transcription of the E1 replicative helicase and E2 transcription/replication factor.  Then, 
expression of the E6 and E7 oncogenes in the infected cells promotes cell cycle progression.  As 
the infected cell progresses through the differentiation pathway, the late HPV promoter is 
activated and the viral structural genes L1 and L2 are expressed.  As the infected cell reaches 
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terminal differentiation, the early and late promoters work to increase production of new virions 
that are shed and can reinfect the surrounding cells (Hebner and Laimins, 2006).   
HPVs have been associated with several types of cancers, including cervical, anogenital 
and oral cancers (De Vuyst et al., 2009; Frisch et al., 1997; Pascual et al., 2007; Tran et al., 
2007b; Walboomers et al., 1999).  This correlation has led to the classification of HPVs based on 
the likelihood of cellular progression to malignancy (Munger et al., 2004).  Most HPVs such as 
types 6 and 11 are low-risk and maintain their genome in an episomal form.  Low-risk HPV 
infections are either cleared by the host immune system or persist in recurrent warts.  However, 
the genomes of the high-risk HPVs, most prevalent of which are types 16 and 18, are commonly 
found integrated into the host genome, often disrupting the viral E1 and E2 genes that function to 
regulate the viral E6 and E7 oncogenes.  This integration is usually followed by over-expression 
of E6 and E7, which can begin the cascade toward carcinogenesis (Munger et al., 2004). 
1.2.1 Human Papillomavirus Oncogenes 
High-risk HPVs have two potent oncogenes, E6 and E7, which help to transform healthy, normal 
cells into cancer cells.  These oncogenes cooperatively work to disrupt host cell cycle control 
mechanism.  High-risk HPV E6 targets many cellular proteins to aid in cellular proliferation, 
transformation, and immortalization (Figure 1).  E6 prevents p53-mediated growth arrest by the 
ubiquitination and subsequent proteasome-mediated degradation of p53 by the E6-E6AP-p53 
tripartate complex (Huibregtse et al., 1991; Scheffner et al., 1990; Werness et al., 1990).  
Although E6 reduces the net levels of p53, additional p53 may be activated in response to stress 
including DNA damage.  E6 binds to the histone acetyltransferases p300 and CBP and prevents 
their ability to acetylate and stabilize p53 (Kumar et al., 2002; Patel et al., 1999; Zimmermann et 
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al., 1999).  E6 also targets ADA3, another histone acetyltransferase, for ubiquitin-mediated 
degradation thereby preventing it from acetylating and stabilizing p53 (Kumar et al., 2002; Patel 
et al., 1999; Zimmermann et al., 1999).  High-risk E6 prevents cell death by directly binding to 
the TNF receptor 1 (Filippova et al., 2002) and by interacting with FADD, caspase 8, BAK, 
BAX, and IRF3 (Filippova et al., 2004; Garnett et al., 2006; Ronco et al., 1998; Thomas and 
Banks, 1998, 1999).  To help immortalize cells, E6 binds E6AP and activates the telomerase 
promoter via interacting with repressors (USF1/2, NFX1-91) and activators (c-myc/max, Sp1, 
NFX1-123, and histone acetyltransferase complexes) (Howie et al., 2009).  The high-risk E6 
protein interacts with and causes the proteasome-mediated degradation of PDZ domain-
containing proteins, including hDlg and hScrib, which disrupt cell adhesion and polarity 
(Thomas et al., 2008).   
 
 
Figure 1: HPV-16 E6 Cellular Interactions 
(Moody and Laimins, 2010, with permission) 
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High-risk HPV E7 functions in collaboration with E6 by targeting additional cellular 
proteins and further promoting cellular proliferation and transformation (Figure 2).  The 
Retinoblastoma protein (pRb) is one of the main regulators of cellular entry into the S-phase.  E7 
binds to hypophosphorylated pRb, as well as to the other related pocket proteins p107 and p130.  
The E7 binding mediates the degradation of pRb, thereby releasing the E2F transcription factors 
to act on promoters of S-phase-specific genes (Boyer et al., 1996; Chellappan et al., 1992; Jones 
et al., 1997b; Zerfass et al., 1995).  High-risk E7 binds to and neutralizes the CDK inhibitors p21 
and p27, thereby increasing the levels of cyclin A and cyclin E, which increases cellular levels of 
CDK2 and promotes the entry of the cells into the S-phase (Funk et al., 1997; Jones et al., 1997a; 
Zerfass-Thome et al., 1996).  Furthermore, E7 binds to histone deacetylases (HDACs) which 
results in increased E2F2-mediated transcription and entry of the cells into the S-phase 
(Longworth et al., 2005).  E7 also acts to prevent the interferon response by binding to IRF1 and 
p48, thereby preventing activation of the Stat1-Stat2 transcription factors (Barnard and 
McMillan, 1999; Park et al., 2000).   
High-risk HPV E5 has emerged as a potential oncoprotein, and has functions that can 
potentiate E6 and E7 mediated cellular transformation (Bouvard et al., 1994; Valle and Banks, 
1995).  The HPV-16 E5 gene can transform murine fibroblasts and human keratinocytes, and 
contributes to skin carcinogenesis in mice (Maufort et al., 2007; Straight et al., 1993; Valle and 
Banks, 1995).  E5 activates the EGFR signaling pathway, which results in increased 
angiogenesis and cell proliferation, and decreased apoptosis (DiMaio and Mattoon, 2001; 
Genther Williams et al., 2005).  Most studies of E5 have been in an overexpression model, and 
its functional in vivo role is less understood. 
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Figure 2: HPV-16 E7 Cellular Interactions 
(Moody and Laimins, 2010, with permission) 
 
1.2.2 Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck  
HPV is considered a major cause of oropharyngeal cancer in developed countries because it is 
detected in 45-90 percent of these cancers (D'Souza et al., 2007; Kreimer et al., 2005; Nasman et 
al., 2009).  HPVs have also been detected in 24 percent of laryngeal and 23 percent of oral cavity 
cancers (Hobbs et al., 2006; Kreimer et al., 2005).  High-risk HPV-16 accounts for 90-95 percent 
of HPV-positive oropharyngeal cancers, while the remaining five percent are caused by high-risk 
HPV-18, -31, -33, and -35 (Gillison et al., 2012; Gillison et al., 2000; Mork et al., 2001; Snijders 
et al., 1996; Zhang et al., 2004).  In the United States, oropharyngeal cancer rates are on the rise 
despite a general decline in tobacco use, consistent with an increase in the number of HPV-
associated SCCHN cases (Chaturvedi et al., 2008; Marur et al., 2010; Nasman et al., 2009).   
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HPV-positive and HPV-negative SCCHN show different clinical and demographic 
characteristics, leading some to classify them as distinct diseases (Vidal and Gillison, 2008).  As 
summarized in Table 1, HPV-positive SCCHN typically arise in the oropharynx area with 
detection rates of up to 50 percent or more, while HPV-negative SCCHN arise in all head and 
neck sites (Hammarstedt et al., 2006; Klussmann et al., 2001; Paz et al., 1997; Venuti et al., 
2004; Vidal and Gillison, 2008).  Patients with HPV-positive SCCHN are diagnosed at a younger 
age (40-60 years) compared to patients with HPV-negative SCCHN (> 60 years) (Cruz et al., 
1996; D'Souza et al., 2007; Fakhry et al., 2008; Mellin et al., 2000; Smith et al., 2004).  SCCHN 
is predominantly a male disease with a 3:1 ratio of men:women, and most often occurs in white 
educated men who are frequently of higher socioeconomic status (D'Souza et al., 2007; Fakhry et 
al., 2008; Gillison et al., 2008).  
The emergence of and increase in HPV-associated SCCHN has led to new risk factors for 
SCCHN.  While the risk factors for HPV-negative SCCHN include alcohol consumption and/or 
tobacco use, the risk factors for HPV-positive SCCHN include oral HPV infection caused by 
sexual behavior (Table 1).  A case-control study showed that a high number of vaginal or oral 
sex partners was associated with high oropharyngeal cancer rates, with the majority of those 
cancers testing positive for HPV (D'Souza et al., 2007).  HPV-positive SCCHN tumors have 
infrequent p53 mutations, but p53 expression is usually low due to inactivation of p53 by the 
HPV E6 protein (Moody and Laimins, 2010; Poeta et al., 2007; van Houten et al., 2002).  The E7 
oncoprotein expressed in HPV-positive SCCHN reduces pRb and cyclin D levels.  Since pRb 
negatively regulates p16, the reduction/loss of pRb in HPV-positive SCCHN causes an increase 
in p16 levels.  However in HPV-negative SCCHN, p16 expression is reduced, usually due to 
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mutations, deletions, or methylation of the p16 gene (Table 1) (Olshan et al., 1997; Rischin et al., 
2010).   
 
Table 1: HPV-positive and HPV-negative SCCHN characteristics 
 HPV-positive HPV-negative 
Anatomic site Oropharynx (tonsil, base of tongue) All sites 
Age Younger Older 
Gender 3:1 men 3:1 men 
Risk factors Sexual behavior Alcohol and tobacco 
Incidence Increasing Decreasing 
p53 mutations Rare > 50 percent 
p16 expression High Low 
Response to treatment Better Worse 
Survival High Low 
 
A large meta-analysis of several published reports of SCCHN showed that patients with 
HPV-positive SCCHN have a lower risk of recurrence and mortality compared to patients with 
HPV-negative SCCHN (Ragin and Taioli, 2007).  Several studies have shown that tumors 
positive for HPV DNA responded better to chemotherapy, radiation, and surgery compared to 
tumors lacking the HPV DNA (Fakhry et al., 2008; Tran et al., 2007b; Vidal and Gillison, 2008; 
Worden et al., 2008).  Additionally, individuals with HPV-positive SCCHN have a better 
prognosis compared to those with HPV-negative SCCHN, with 95 percent of patients with HPV-
positive SCCHN still alive after two years, compared to only 62 percent of patients with HPV-
negative SCCHN (Fakhry et al., 2008).   
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1.3 MICRORNAS 
MicroRNAs (miRNAs) are endogenously encoded single-stranded RNAs that most commonly 
function as negative regulators of gene expression.  MiRNAs were discovered in Caenorhabditis 
elegans in 1993 by Victor Ambrose (Lee et al., 1993) and are predicted to regulate the 
expression of up to a third of all genes (Lewis et al., 2005). 
1.3.1 MicroRNA Biogenesis 
The majority of miRNAs are transcribed by RNA polymerase II into a primary miRNAs (pri-
miRNA) containing a stem-loop structure (Figure 3) (Lee et al., 2004).  Pri-miRNAs are capped 
and polyadenylated (Cai et al., 2004) and then processed into a 60-80 bp imperfectly paired 
stem-loop precursor (pre) miRNA by the RNase III enzyme Drosha and its cofactor 
Pasha/DGCR8 (Gregory et al., 2004).  The pre-miRNA is actively transported out of the nucleus 
to the cytoplasm by Ran-GTP and Exportin 5 (Lund et al., 2004) where the RNase III enzyme 
Dicer recognizes the two-nucleotide 3’ overhang of the pre-miRNA and cleaves it into a 21-24 
nucleotide miRNA duplex (Hutvagner et al., 2001).  The miRNA duplex is loaded into the RNA-
Induced Silencing Complex (RISC), and only the mature miRNA strand is retained (Kawamata 
et al., 2009).  The RISC contains a member of the Argonaute protein family, a double-stranded 
RNA binding protein TRBP, and Dicer (Chendrimada et al., 2005).  The mature miRNA guides 
the RISC to complementary sites in the 3’ untranslated region (UTR) of the target mRNA where 
depending upon the degree of complementarity, the miRNA-RISC will either repress the 
translation of the target mRNA or target the mRNA for degradation (Eulalio et al., 2008).  The 5′ 
2-8 nt of the miRNA, known as the seed sequence, is usually complementary to the mRNA 
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target, and the remaining miRNA-mRNA interaction contains many mismatches.  MiRNAs with 
low complementarity to the target mRNA generally promote translational repression of the 
mRNA whereas miRNAs with greater complementarity to the mRNA generally target the 
mRNA for degradation (see Figure 3) (Eulalio et al., 2008; Martinez et al., 2002).  Since 
miRNAs do not have to be fully complementary to the target mRNA, one miRNA can regulate 
many genes, and one gene can be regulated by many miRNAs (John et al., 2004; Kiriakidou et 
al., 2004; Krek et al., 2005; Lewis et al., 2003; Lim et al., 2005).   
 
 
Figure 3: MicroRNA Biogenesis 
(Esquela-Kerscher and Slack, 2006, with permission) 
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1.3.2 MicroRNA Involvement in Cancer 
The small percentage of miRNAs that have been characterized function in many cellular 
regulatory processes.  Recently, many miRNAs have been shown to function as tumor 
suppressors or oncogenes, and the dysregulation of such miRNAs has been shown to correlate 
with tumor progression (Figure 4) (Esquela-Kerscher and Slack, 2006).  Up to one-half of well-
studied miRNA genes are located in fragile sites of the genome, where genomic disruption often 
leads to cancer (Calin et al., 2004).  Low expression of a tumor suppressive miRNA can lead to 
lack of repression of its target oncogenes, whereas high expression of an oncogenic miRNA can 
lead to repression of its target tumor suppressor genes.  Both types of such events can then lead 
to cancer (Figure 4) (Esquela-Kerscher and Slack, 2006).  Global miRNA dysregulation as well 
as dysregulation of miRNA processing machinery is seen in many tumors (Caldas and Brenton, 
2005; Esquela-Kerscher and Slack, 2006; Lu et al., 2005).   
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Figure 4: Tumor suppressive and Oncogenic MicroRNAs 
(Esquela-Kerscher and Slack, 2006, with permission) 
 
The first miRNA shown to act as a tumor suppressor was the miR-15a-miR-16-1 cluster 
in B-cell chronic lymphocytic leukemia (CLL) (Calin et al., 2002).  More than half of all CLL 
cases have deletions in the miR-15a and miR-16 chromosomal regions, and these miRNAs are 
downregulated or deleted in several other types of cancers.  These tumor suppressor miRNAs are 
known to target Bcl-2, cyclin D1, and Wnt3a (Bandi et al., 2009; Bonci et al., 2008; Cimmino et 
al., 2005).  MiR-143 and miR-145 are downregulated in colorectal and bladder tumors and 
breast, cervical, lymphoid, and prostate cancer cell lines (Esquela-Kerscher and Slack, 2006; 
Michael et al., 2003; Villadsen et al., 2012).  The genes encoding the let-7 family of miRNAs are 
 14 
located in fragile sites that are linked to breast, cervical, lung, and urothelial cancers (Calin et al., 
2004).  The downregulation of these let-7 family members in lung cancer correlates with poor 
prognosis and survival (Takamizawa et al., 2004).  Furthermore, miRNAs in the let-7 family 
target the Ras oncogene; therefore decreased expression of these miRNAs leads to increased cell 
survival and cancer (Johnson et al., 2005).   
One of the most well studied oncogenic miRNAs is miR-21.  This was one of the first 
miRNAs to be identified in humans and is overexpressed in almost all cancers, where it promotes 
cell survival (Asangani et al., 2008; Chan et al., 2005; Fujita et al., 2008; Park et al., 2009a; Si et 
al., 2007; Zhu et al., 2008).  High levels of miR-21 have been found in breast, cervical, colon, 
head and neck, hepatocellular, lung, ovarian, pancreatic, prostate, stomach, and thyroid cancers, 
as well as glioblastoma and leukemia (Asangani et al., 2008; Frankel et al., 2008; Krichevsky 
and Gabriely, 2009; Lu et al., 2008b; Meng et al., 2007; Si et al., 2007).  The miR-17~92 cluster, 
known as “oncomiR-1”, is often amplified and overexpressed in B cell lymphomas and small 
cell lung cancer (Hayashita et al., 2005; Matsubara et al., 2007; Ota et al., 2004).  The c-Myc 
oncogene is often upregulated in many cancers, and it serves as a transcription factor for the 
miR-17~92 miRNA cluster (He et al., 2005; O'Donnell et al., 2005; Sylvestre et al., 2007).  The 
c-Myc protein also represses miRNA expression by directly binding to the promoters of many 
miRNAs, including let-7a/f/d, miR-15a, miR-16, miR-22, miR-26a/b, miR-29a/b, miR-30c/e, 
miR-34a, and miR-146a (Chang et al., 2008b; Kleine-Kohlbrecher et al., 2006).  There are two 
other miRNA clusters (miR-106a~363 and miR-106b~25) that belong to the miR-17~92 family 
of miRNA clusters, and these miRNA clusters are thought to have arisen through a series of 
deletions and/or duplications, as many of the miRNAs have the same seed sequence and are 
 15 
thought to target similar genes (Ventura et al., 2008).  Thus, since miR-17~92 is an oncogenic 
miRNA cluster, miR-106a~363 and miR-106b~25 are also potential oncogenic miRNA clusters. 
MiRNAs are also involved in signaling pathways that are commonly disrupted in cancer.  
The tumor suppressor protein p53 is mutated in up to 50 percent of cancers, and dysfunctional 
p53 signaling is found in up to 80 percent of tumors (Levine et al., 2004; Levine et al., 2006; 
Olivier et al., 2004).  While p53 regulates several miRNAs, it is also targeted by some miRNAs.  
MiR-504 and miR-125b directly regulate p53 (Hu et al., 2010).  Additionally, miR-29, miR-34a, 
and miR-122 positively regulate p53 through their targets p85α, SIRT1, and cyclin G1, 
respectively (Fornari et al., 2009; Park et al., 2009b; Yamakuchi et al., 2008).  The p53 protein is 
a direct activator of the members of the miR-34 family through its binding to the promoters of 
the miR-34a and miR-34b/c genes (Chang et al., 2007; Corney et al., 2007; He et al., 2007; 
Raver-Shapira et al., 2007; Tazawa et al., 2007).  The miR-34 family members target many 
proteins that regulate the cell cycle, including cyclin E2, CDK4, CDK6, and BCL2.  In cancers 
where p53 is mutated/disrupted, the miR-34 family members are not expressed, and this leads to 
cellular proliferation (Bommer et al., 2007; Chang et al., 2007; Tazawa et al., 2007).  
Additionally, miR-34a is downregulated in cells expressing high-risk HPV E6, which targets p53 
for ubiquitin-mediated degradation (Wang et al., 2009a).  The p53 protein also regulates 
hypoxia-induced signaling by activating miR-107, which targets the hypoxia inducible factor-1β 
(Yamakuchi et al., 2010).  The p53 protein activates the promoter of miR-145, which negatively 
regulates the c-Myc oncogene (Sachdeva et al., 2009) and p53 activates the transcription of miR-
192 and miR-215, which target genes that regulate the cell cycle (Georges et al., 2008).  The 
miR-17~92, miR-106b~25, and miR-106a~92 clusters are regulated by p53 through its 
repression of E2F1 (Brosh et al., 2008).  Finally, p53 interacts with Drosha to enhance Drosha-
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mediated primary miRNA maturation and enhances the expression of miR-16, miR-143, miR-
145, and miR-206 (Suzuki et al., 2009). 
High-risk HPV E6 and E7 proteins are known to interact with many cellular proteins and 
promote cellular transformation (Moody and Laimins, 2010).  Among these interactions, c-Myc 
and p53 are known to be involved in complex networks that involve miRNAs.  Thus, disruption 
of c-Myc and/or p53 by the HPV oncogenes may alter the expression of miRNAs that are 
regulated by or involved in the c-Myc or p53 networks, (Chang et al., 2008b; O'Donnell et al., 
2005; Suzuki et al., 2009).   
 
1.3.3 MicroRNA Involvement in SCCHN 
There have been many reports on dysregulated miRNAs in SCCHN cell lines and tissues.  
Although miRNA expression can vary by site (tonsil, tongue, etc.), there are several commonly 
dysregulated miRNAs in all SCCHN sites.  Some commonly downregulated miRNAs in head 
and neck cancer compared to adjacent normal tissue include miR-375, miR-133a, and miR-133b 
(Avissar et al., 2009; Childs et al., 2009; Hui et al., 2010; Lajer et al., 2011; Tran et al., 2007a; 
Wong et al., 2008a; Wong et al., 2008b).  Known as a tumor suppressive miRNA, low 
expression of miR-375 is associated with low survival of oral cancer patients, reduced cellular 
apoptosis, and increased proliferation (Harris et al., 2012; Nohata et al., 2011b).  The tumor 
suppressive miR-133a is often downregulated in several cancers, including SCCHN, where it 
targets genes that are involved in cell migration and invasion (Kinoshita et al., 2012a; Kinoshita 
et al., 2012b; Nohata et al., 2011a). 
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One commonly overexpressed miRNA in head and neck cancer compared to adjacent 
normal tissue is miR-155 (Chang et al., 2008a; Hui et al., 2010; Lajer et al., 2011; Ramdas et al., 
2009; Wong et al., 2008b).  This miRNA is overexpressed in many cancers, but in Epstein-Barr-
virus-negative nasopharyngeal carcinoma, high expression of miR-155 is associated with poor 
prognosis (Du et al., 2011). 
1.4 PROJECT HYPOTHESIS 
We hypothesized that infection with high-risk HPV would lead to overexpression of the HPV E6 
and E7 oncogenes.  Expression of these oncogenes in SCCHN is expected to disrupt cellular 
miRNA expression differently than in HPV-negative SCCHN.  The altered miRNA expression in 
HPV-positive and HPV-negative SCCHN would lead to alterations in the expression of the target 
gene(s), thus altering pathways involved in HPV-positive and HPV-negative SCCHN.  The 
altered pathways may provide insight into the different characteristics seen in HPV-positive and 
HPV-negative SCCHN. 
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2.0  ALTERATION OF MICRORNA PROFILES IN SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK CELL LINES BY HUMAN 
PAPILLOMAVIRUS 
Work described in this section was published in Head & Neck (Head Neck. 2011 
Apr;33(4):504-12) with authors Abigail I. Wald, Elizabeth E. Hoskins, Susanne I. Wells, Robert 
L. Ferris, and Saleem A. Khan. 
 19 
2.1 INTRODUCTION 
Squamous cell carcinoma of the head and neck (SCCHN) ranks sixth among cancers 
worldwide (Tran et al., 2007b).  Many of these cases are associated with heavy consumption of 
alcohol and/or tobacco use, which over time induce mutations in essential genetic pathways that 
regulate the cell cycle.  However, human papillomavirus (HPV) type 16 DNA has been found in 
up to 30 percent of these cancers, most often in the oropharynx region, and such cases of 
SCCHN are often found in individuals without the risk factors of alcohol and tobacco use 
(Chaturvedi et al., 2008; Tran et al., 2007b).  The HPV-positive SCCHN subset have increased in 
the past 10 years (Chaturvedi et al., 2008).  Because of this demographic shift and distinct 
clinical behavior, the association and relevance of HPV in SCCHN is under intense 
investigation.  
Characteristics of HPV-associated SCCHN are very different from HPV-negative 
SCCHN, causing disputes whether these cancers should be classified as distinct tumors (Vidal 
and Gillison, 2008).  HPV-positive oral tumors often exhibit loss of cell cycle control proteins, 
including pRb and cyclin D1, whereas these two proteins are commonly overexpressed in HPV-
negative oral tumors (Tran et al., 2007b; Vidal and Gillison, 2008).  One of the most common 
tumor suppressor proteins, p53, is mutated in up to half of oral cancers, but is very rarely 
mutated in HPV-positive SCCHN, and tumors with a high viral load have a better prognosis 
compared to tumors with a low viral load or tumors that are HPV-negative (Tran et al., 2007b; 
Vidal and Gillison, 2008).  Patients with HPV-positive oral tumors have a better response to 
chemotherapy, radiation, and surgery (Vidal and Gillison, 2008), and have evidence of immune 
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activation against viral antigens (Albers et al., 2005), despite having frequent metastasis to 
regional lymph nodes (Vidal and Gillison, 2008). The biological basis for the differential 
behavior of HPV-positive SCCHN is not understood. 
Micro (mi) RNAs are small, ~22 nt long, chromosome-encoded single-stranded RNAs 
that are commonly associated with negative regulation of gene expression (Bartel, 2004). 
MiRNAs are transcribed and exported to the cytoplasm where further processing takes place, and 
the mature miRNA strand is incorporated into the RNA-induced silencing complex (Bartel, 
2004). The miRNA guides the RNA-induced silencing complex to the 3′ untranslated region of 
its target mRNA where, depending upon the degree of complementarity, the miRNA either 
translationally represses the mRNA or targets it for degradation (Bartel, 2004).  MiRNA 
dysregulation has been implicated in many different types of human cancers (Esquela-Kerscher 
and Slack, 2006; Tong and Nemunaitis, 2008).   
Previous reports have shown altered miRNA profiles in head and neck cancers compared 
to the normal oral tissue (Childs et al., 2009; Hui et al., 2010; Ramdas et al., 2009; Wong et al., 
2008a).  MiRNAs with high expression in the tumors compared to the normal oral tissue 
included miR-21, whereas miR-125b was downregulated (Childs et al., 2009; Hui et al., 2010; 
Ramdas et al., 2009).  Basal miRNA expression in 9 head and neck cancer cell lines found that 
33 miRNAs were expressed at a high level and 22 miRNAs were expressed at a low level (Tran 
et al., 2007a).  Interestingly, one of these cell lines UM-SCC47, is HPV-16-positive (Bradford et 
al., 2003).  In all 9 cell lines, let-7a, miR-16, miR-21, and miR-205 were highly expressed, and 
miR-342, miR-346, and miR-373* were expressed at low levels (Tran et al., 2007a).  Although 
these studies show alterations in miRNA levels in head and neck cancer, they do not address the 
role of HPVs.  Because the number of cases of HPV-16-positive SCCHN have been increasing in 
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the past 10 years (Chaturvedi et al., 2008), and the characteristics of HPV-positive and HPV-
negative SCCHN support distinction between these cancers (Vidal and Gillison, 2008), we 
sought to analyze the miRNA profiles in HPV-positive and HPV-negative SCCHN cell lines.  
In this study, we demonstrate that miRNA expression profiles in HPV-16-positive 
SCCHN cells are distinctly different from those in HPV-negative SCCHN cells and in normal 
oral keratinocytes (NOKs) that have been immortalized by activation of h-TERT.  Using human 
foreskin keratinocytes (HFKs) expressing either the HPV-16 E6 or E7 oncogene, we also 
demonstrate that expression of the E6 oncogene results in upregulation of miR-363 and 
downregulation of miR-181a, mR-218 and miR-29a.  Furthermore, siRNA knockdown of HPV-
16 E6 in the HPV-positive SCCHN cell line SCC2 reduces the expression of miR-363. 
2.2 MATERIALS AND METHODS 
2.2.1 Cell Lines 
The cell lines used in this study are described in Table 2.  Two HPV-16-positive SCCHN cell 
lines, UD-SCC-2 (gift from Dr. Henning Bier, University of Dusseldorf) (Gwosdz et al., 2005), 
and UPCI:SCC90 (Ferris et al., 2005), and two HPV-negative SCCHN cell lines, PCI-13 and 
PCI-30 (gifts from Dr. Theresa Whiteside, UPCI) (Chikamatsu et al., 1999) were used for 
miRNA expression profile analysis.  The HPV-16-positive SCCHN cell lines UM-SCC47 (gift 
from Dr. Thomas Carey, University of Michigan) (Bradford et al., 2003; Brenner et al., 2010) 
and 93-VU-147T (gift from Dr. Hans Joenje, VU Medical Center Van der Boechorststraat 7, The 
Netherlands) (Steenbergen et al., 1995) were used with the above cells lines for validation of the 
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miRNA microarrays.  The UPCI:SCC90, UM-SCC-47, ad 93-VU-147T cell lines contain 
integrated HPV-16 DNA, whereas the HPV-16 status (integrated vs. episomal) of the UD-SCC-2 
cell line is not known (Ferris et al., 2005; Gupta et al., 2009; Steenbergen et al., 1995).  
However, all the HPV-16-positive cell lines were shown to express the viral E6 and E7 genes 
(Figure 5B).  The UD-SCC-2, UPCI:SCC90, UM-SCC47, PCI-13 and PCI-30 cell lines were 
grown in Dulbecco’s modified Eagle’s medium (Lonza, Walkersville, MD) supplemented with 
10% fetal bovine serum, 1% penicillin/streptomycin, and 2% L-glutamine at 37°C in the 
presence of 5% CO2.  The 93-VU-147T cell line was grown in Dulbecco’s modified Eagle’s 
medium/F12 medium (MediaTech, Manassas, VA) supplemented with 10% fetal bovine serum, 
1% penicillin/streptomycin, and 2% L-glutamine at 37°C in the presence of 5% CO2.  NOKs that 
were immortalized by activation of h-TERT (Piboonniyom et al., 2003) were grown in defined 
keratinocytes serum-free medium (Gibco, Grand Island, NY) supplemented with bovine pituitary 
extract and 1% penicillin/streptomycin at 37°C in the presence of 5% CO2.  Primary HFKs that 
were transduced with an LXSN-based retroviral vector expressing high-risk HPV-16 E6 or E7 
were grown in EpiLife medium (Invitrogen, Carlsbad, CA) supplemented with human 
keratinocytes growth supplements (Invitrogen) and 1% penicillin/streptomycin at 37°C in the 
presence of 5% CO2. 
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Table 2: SCCHN cell line characteristics 
SCCHN Sample TNM Classification Specimen Site Sex HPV-status p53 gene 
PCI-13 T4N1M0 Oral Cavity Male HPV-negative E286K 
PCI30 T3N1M0 Oral Cavity Male HPV-negative wt 
UD-SCC2 T1N2M0 Hypopharynx Male HPV-16 wt 
UPCI:SCC90 T2N1M0 Base of Tongue Male HPV-16 wt 
UM-SCC47 T3N1M0 Lateral Tongue Male HPV-16 wt 
93-VU-147T T4N2 Floor of Mouth Male HPV-16 wt 
 
2.2.2 Human Papillomavirus Status of Samples 
The SCCHN cell lines were confirmed to be either HPV-positive or HPV-negative by 
polymerase chain reaction (PCR) analysis using the MY09/MY11 primer set, which amplifies a 
conserved region of the HPV L1 gene (Ferris et al., 2005).  Although the HPV-positive SCCHN 
cell lines have previously been characterized (Bradford et al., 2003; Ferris et al., 2005; Gwosdz 
et al., 2005), we confirmed the HPV status of these cells.  UD-SCC-2, UPCI:SCC90, UM-
SCC47, and 93-VU-147T were further confirmed to contain HPV-16 DNA by PCR using 
primers that amplify a 477-bp region of the HPV-16 E6 gene using 5′-
ATGCACCAAAAGAGAACTGC-3′ as the forward primer and 5′-
TTACAGCTGGGTTTCTCTAC-3′ as the reverse primer.  The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was used as a loading control using 5′-
AGGGGAGATTCAGTGTGGTG-3′ as the forward primer and 5′-
GGCCTCCAAGGAGTAAGACC-3′ as the reverse primer, amplifying a 122-bp region.  All 
PCR reactions were performed as described previously (Ferris et al., 2005).  The PCR amplified 
DNA was analyzed by agarose gel electrophoresis.  
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2.2.3 RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction Analysis 
Total RNA was isolated from all the cell lines grown to 90% confluency using the Ultraspec™ 
RNA Isolation System (Biotecx, Houston, TX, USA).  DNase-I-treated total RNA (1 µg) of UD-
SCC-2, UPCI:SCC90, UM-SCC47, and 93-VU-147T was subjected to reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis for expression of the HPV-16 E6 and E7 
oncogenes using the Advantage® Clontech RT-for-PCR Kit (Clontech, Mountain View, CA, 
USA) according to the manufacturer’s instructions.   
The HPV-16 E6 gene was amplified using the primer set described above, and expression 
of the HPV-16 E7 gene was done using the forward primer 5′-
CAGCTCAGAGGAGGAGGATG-3′ and the reverse primer 5′-
GCACAACCGAAGCGTAGAGT-3′, amplifying a 115-bp region.  Expression of the GAPDH 
gene was used as a control, using the primer set described above.  The PCR products were 
analyzed by agarose gel electrophoresis (Fig. 5B).  The HFK-16E6 and HFK-16E7 cell lines 
were also confirmed to be expressing the intended oncogene via RT-PCR as described above.   
2.2.4 MicroRNA Microarray Analysis 
Small RNAs (<200 nt) were enriched from total RNA from 2 HPV-positive SCCHN cell lines 
(UD-SCC-2 and UPCI:SCC90) and 2 HPV-negative SCCHN cell lines (PCI-13 and PCI-30) 
using the RNeasy Mini Kit and the RNeasy MinElute Clean Up Kit (Qiagen, Valencia, CA).  
The small RNA fractions were validated on a 15% acrylamide gel.  Small RNA fractions 
obtained from 5 µg of total RNA were labeled with AlexaFluor 647 (Invitrogen) using the 
mirVana Labeling Kit and hybridized (in duplicate) to the mirVana miRNA Bioarrays V2 
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(Ambion, Austin, TX).  These bioarrays contained 662 antisense oligonucleotides, spotted in 
quadruplicate, which included 328 known human miRNAs, 152 predicted miRNAs (ambi-
miRNAs), 266 mouse miRNAs (114 unique miRNAs), and 238 rat miRNAs (46 unique 
miRNAs).  The arrays were hybridized with labeled miRNAs at 42°C overnight.  Each array was 
subsequently washed once in low stringency was solution followed by washing twice in high 
stringency was solution, and dried by centrifugation.  The arrays were immediately scanned 
using the GenePix 4000B scanner and the median fluorescent intensities, minus the background 
fluorescence, were obtained using the GenePix Pro 6.0 software.  The median fluorescent 
intensities of each spot on the bioarrays were log2 transformed and normalized using the mean 
intensities within the array and the global mean adjustment between the arrays by the GEDA 
program (http://bioinformatics.upmc.edu/GE2/GEDA.html).  Significance Analysis of 
Microarray program version 1.21 (http://www-stat.stanford.edu/~tibs/SAM/) was used to 
perform a t test to obtain the differential miRNA expression patterns of each sample.  MiRNAs 
with at least a 2-fold change in expression with a q-value (false discovery rate) of zero were 
considered to have significant changes in their expression between the samples.  
2.2.5 SiRNA Knockdown of Human Papillomavirus-16 E6 and Transfection Assays 
The role of HPV-16 E6 in altered miRNA expression in HPV-positive SCCHN cell lines was 
analyzed using double-stranded siRNA against HPV-16 E6 (siRNA 209 complementary to E6 
positions 277 to 298, sense sequence 5’-UCCAUAUGCUGUAUGUGAUTT-3’; Dharmacon, 
Lafayette, CO) (Jiang and Milner, 2002; Tang et al., 2006).  The HPV-positive SCCHN cell line 
SCC2 was seeded (1.5 x 105) into 6-well plates, and after 24 hours transfected with 125 nM 
siRNA using Lipofectamine 2000 Reagent (Invitrogen) and OPTI-MEM I (Gibco).  BLOCK-iT 
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fluorescent oligo (Invitrogen) was used as a negative control siRNA (it has no human 
homologous sequences) and a transfection efficiency control.  Cells were harvested after 72 
hours, and RNA extractions were done as previously described. 
2.2.6 Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction 
Array data were confirmed by real-time quantitative RT-PCR (qRT-PCR) using the TaqMan 
MicroRNA Reverse Transcription Kit and the TaqMan MicroRNA Assays (Applied Biosystems, 
Foster City, CA) and the Real-Time Thermocycler iQ5 (Bio-Rad, Hercules, CA).  These assays 
use stem-loop primers designed to amplify only the mature miRNA.  DNase I-treated total RNA 
(5 ng) was used for each reaction, and all reactions were done in triplicate.  Assays were 
performed in accord with the manufacturer’s instructions and the miRNA levels were normalized 
to the small nucleolar RNU43 levels.  Relative expression levels of the miRNAs were calculated 
using the 2-∆∆CT values (Livak and Schmittgen, 2001).  Statistical analysis was done via a 2-tailed 
t test.  
HPV-16 E6 expression in siRNA knockdown experiments was confirmed via qRT-PCR 
using the QuantiTect SYBR Green PCR kit (Qiagen) in accord with the manufacturer’s 
instructions.  The E6 gene was amplified using the forward primer 5′-
AGCGACCCAGAAAGTTACCA-3′ and the reverse primer 5′-
GCATAAATCCCGAAAAGCAA-3′, amplifying a 134-bp region.  The E6 mRNA levels were 
normalized to the GAPDH gene, using the primer set described above.  DNase I-treated total 
RNA (1 µg) was used for each reaction, and all the reactions were done in triplicate.  The E6 
mRNA levels were normalized to the GAPDH levels, and relative expression levels were 
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calculated using the 2-∆∆CT values (Livak and Schmittgen, 2001).  Statistical analysis was done 
via a 2-tailed t test. 
2.3 RESULTS 
2.3.1 MicroRNA Expression in Squamous Cell Carcinoma of the Head and Neck Cell 
Lines 
The UD-SCC-2, UPCI:SCC90, UM-SCC47, and 93-VU-147T cell lines were confirmed to be 
HPV-positive by PCR analysis using the MY09/MY11 primers (Figure 5A).  These cell lines 
were further confirmed to contain HPV-16 DNA by PCR using E6 gene primers (Figure 5A).  
Finally, the expression of the HPV-16 E6 and E7 genes in these cell lines was confirmed by RT-
PCR analysis (Figure 5B).  We then analyzed miRNA expression in 2 HPV-16-positive (UD-
SCC-2 and UPCI:SCC90) and 2 HPV-negative (PCI-13 and PCI-30) SCCHN cell lines utilizing 
miRVana miRNA Bioarrays V2.  MiRNA analysis showed that 129 human miRNAs were 
expressed in both of the HPV-negative cell lines (PCI-13 and PCI-30), with miR-21, miR-16, 
and miR-29a being the most highly expressed (Supplementary Table 1).  The HPV-16-positive 
cell lines (UD-SCC-2 and UPCI:SCC90) both expressed 216 human miRNAs, indicating a 
general upregulation of miRNA expression in the presence of HPV-16 DNA.  The miRNAs with 
high basal expression included miR-205, miR-16, and miR-21 (Supplementary Table 2). 
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Figure 5: HPV status of SCCHN cell lines 
(A) PCR of all SCCHN cell lines to check HPV status. (B) RT-PCR for HPV-16 E6 and E7 expression 
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2.3.2 MicroRNA Expression is Altered in Human Papillomavirus-16-Positive Squamous 
Cell Carcinoma of the Head and Neck Cell Lines 
We compared the miRNA expression profiles in 2 HPV-16-positive cell lines, SCC2 and SCC90, 
with that of 2 HPV-negative cell lines, PCI13 and PCI30.  Two human miRNAs, miR-363 and 
miR-33, and the rat miRNA miR-497 (which differs from human miR-497 by just 1 nucleotide), 
were upregulated in HPV-positive cell lines compared to HPV-negative cell lines (Table 3).  
Eight human miRNAs and 1 predicted human miRNA were downregulated in HPV-positive cell 
lines (Table 3).  A comparison of miRNA expression between individual cell lines showed that 2 
miRNAs were downregulated in SCC2 compared to PCI13 (Supplementary Table 3), whereas 6 
miRNAs were overexpressed in SCC2 compared to PCI30 (Supplementary Table 4).  When 
SCC90 was compared to PCI13, 4 miRNAs were overexpressed and 3 miRNAs were 
underexpressed (Supplementary Table 5).  On the other hand, 10 miRNA were overexpressed in 
SCC90 compared to PCI30 (Supplementary Table 6).  MiR-363 was upregulated in SCC90 
compared to both PCI13 and PCI30 cell lines, and in SCC2 compared to PCI30 (Supplementary 
Tables 4-6).  We also found that miR-181a was downregulated in both SCC2 and SCC90 
compared to PCI13 (Supplementary Tables 3 and 5).  Although there were differences in miRNA 
expression in individual SCCHN cell lines, several miRNAs including miR-363 and miR-181a 
were similarly altered in both the HPV-positive cell lines in individual and pair-wise 
comparisons with the 2 HPV-negative cell lines. 
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Table 3: MiRNAs differentially expressed in HPV-16-positive SCCHN cell lines compared to HPV-negative 
SCCHN cell lines 
MiRNA Fold Change * 
Overexpressed 
   hsa_miR_363 
   rno_miR_497 
   hsa_miR_33 
 
5.16 
3.20 
1.99 
Underexpressed 
   hsa_miR_155 
   hsa_miR_181a 
   hsa_miR_181b 
   hsa_miR_29a 
   hsa_miR_218 
   hsa_miR_222 
   hsa_miR_221 
   hsa_miR_142_5p 
   ambi_miR_13232 
 
-7.60 
-7.34 
-6.76 
-4.68 
-4.22 
-3.69 
-3.38 
-3.20 
-3.10 
Abbreviations: MiRNA, microRNA; HPV, human papillomavirus; SCCHN, squamous cell carcinoma of 
the head and neck; miR, microRNA; hsa, human; rno, rat; ambi, Ambion predicted. *Mean fold changes 
in HPV-16-positive SCCHN cell lines UD-SCC-2 and UPCI:SCC90 compared to HPV-negative SCCHN 
cell lines PCI-13 and PCI-30.  The q-values of all miRNAs were 0. 
 
2.3.3 Human Papillomavirus-16-Positive Squamous Cell Carcinoma of the Head and 
Neck Cell Lines have Altered MicroRNA Expression as Compared to Both Human 
Papillomavirus-Negative Squamous Cell Carcinoma of the Head and Neck Cell Lines and 
Immortalized Normal Oral Keratinocytes 
To validate the microarray data, we carried out qRT-PCR analysis for selected miRNAs that 
were found to be differentially expressed in SCC2 and SCC90 (HPV-positive) cell lines 
compared to PCI13 and PCI30 (HPV-negative).  For this, we used 4 HPV-16-positive SCCHN 
cell lines (2 that were included in the array analysis and 2 that were not) and 2 HPV-negative 
SCCHN cell lines.  To exclude miRNA profiles only associated with squamous differentiation or 
immortalization, we also used an NOK cell line that has been immortalized by activation of h-
TERT (Piboonniyom et al., 2003).  The most overexpressed miRNA in the HPV-positive cells 
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based on the array analysis was miR-363.  The qRT-PCR results showed higher expression of 
miR-363 in HPV-positive cell lines SCC2 (6.3-fold), SCC90 (28.9-fold), SCC47 (1.3-fold), and 
93-VU-147T (5.5-fold) compared to NOK cells (Figure 6A).  The expression of miR-363 in the 
HPV-negative cell lines was reduced 12-fold in PCI13 and 7-fold in PCI30 cells compared to the 
NOK cells (Figure 6A).  MiR-363 was upregulated in the above 4 HPV-positive SCCHN cell 
lines by 61.7-fold, 283.1-fold, 12.8-fold, and 54.4-fold, respectively, compared to the average 
expression in PCI13 and PCI30, with p < .01 (Figure 6A).  Because miR-363 is part of a cluster 
of miRNAs, we carried out qRT-PCR analysis for 2 other miRNAs in the cluster, miR-106a and 
miR-92a.  There was no difference in expression of these miRNAs in the HPV-positive SCCHN 
cell lines compared to the HPV-negative SCCHN cell lines (data not shown).  The Ambion 
miRVana miRNA microarray includes a probe for both rat and human miR-497.  The rat miR-
497 differs from the human miR-497 by the addition of 1 adenosine at its 3′ end (Griffiths-Jones 
et al., 2008).  Because the rat miR-497, but not the human miR-497, was significantly altered in 
the HPV-positive samples as compared to the HPV-negative samples in our array analysis, we 
also carried out qRT-PCR analysis for this miRNA.  These results showed that human miR-497 
was upregulated in 3 HPV-positive cell lines, SCC2 (17.2-fold), SCC90 (6.8-fold), and 93-VU-
147T (1.61-fold) compared to the NOK cells (Figure 6B).  This miRNA was slightly 
downregulated in HPV-negative PCI13 (1.8-fold) and PCI30 (2.0-fold) cells relative to the NOK 
cells (Figure 2B).  MiR-497 was upregulated in the above 3 HPV-positive SCCHN cell lines by 
32.6-fold, 13.0-fold, and 3.1-fold, respectively, compared to the average expression in PCI13 and 
PCI30, with p < .01 (Figure 6B).   
The array results also showed that 8 human miRNAs, and 1 predicted human miRNA 
were downregulated in 2 HPV-positive cell lines, SCC2 and SCC90, compared to the HPV-
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negative cell lines (Table 3).  The downregulation of a few selected representative miRNAs in 4 
HPV-positive cell lines as compared to both the HPV-negative cell lines and NOK cells was 
confirmed by qRT-PCR.  MiR-155 was downregulated in SCC2 (36.7-fold), SCC90 (87.4-fold), 
SCC47 (2.9-fold), and 93-VU-147T (1.4-fold) compared to the NOK cells (Figure 6C).  This 
miRNA was downregulated in the 4 HPV-positive cell lines by 42.7-fold, 101.7-fold, 3.4-fold, 
and 1.6-fold, respectively, compared to the average expression in the PCI13 and PCI30 cell lines, 
with p < .01 for SCC2, SCC90, and SCC47, and p < .05 for 93-VU-147T (Figure 6C).  MiR-
181a was downregulated in SCC2 (212.3-fold), SCC90 (8.7-fold), SCC47 (7.3-fold), and 93-
VU-147T (3.4-fold) compared to the NOK cells (Figure 6D).  This miRNA was downregulated 
in the above 4 HPV-positive cell lines by 91.4-fold, 3.7-fold, 3.1-fold, and 1.6-fold, respectively, 
compared to the average expression in the PCI13 and PCI30 cell lines, with p < .01 for SCC2, 
SCC90, and SCC47 (Figure 6D).  Similarly, miR-218 was downregulated in SCC2 (43.3-fold), 
SCC90 (28.5-fold), SCC47 (1.4-fold), and 93-VU-147T (35.1-fold) compared to the NOK cells 
(Figure 6E).  This miRNA was downregulated in the above 4 HPV-positive cell lines by 141.9-
fold, 93.4-fold, 4.6-fold, and 114.7-fold, respectively, compared to the average expression in the 
PCI13 and PCI30 cell lines, with p < .01 for SCC2, SCC90, and 93-VU-147T, and p < .05 for 
SCC47 (Figure 6E).  Finally, miR-29a was downregulated in SCC2 (144.8-fold), SCC90 (59.9-
fold), SCC47 (26.5-fold), and 93-VU-147T (22.3-fold) compared to the NOK cells (Figure 6F), 
whereas this miRNA was downregulated 18.3-fold, 7.6-fold, 3.4-fold, and 2.8-fold, respectively, 
compared to the average values of PCI13 and PCI30 cell lines, with p < .01 for SCC2, SCC90, 
and SCC47, and p < .05 for 93-VU-147T (Figure 6E). 
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Figure 6: QRT-PCR validation of microRNA expression data in 4 HPV-positive and 2 HPV-negative SCCHN 
cell lines, and NOK cells 
No RT, no reverse transcriptase added.  Intensity values are relative to the NOK cells, which were arbitrarily 
assigned a value of 1 or -1.  The p values for the HPV-positive cell lines compared to the 2 HPV-negative SCCHN 
cell lines are indicated by * (p < .05) and ** (p < .01). 
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2.3.4 Human Papillomavirus-16 E6 Oncogene Alters MicroRNA Expression 
To test whether the altered miRNA expression in the HPV-positive SCCHN cell lines was due to 
the expression of the HPV-16 oncogenes, we used primary HFKs transduced with either the 
empty vector (LXSN) or vectors expressing the high-risk HPV-16 E6 or E7.  Analysis of RNA 
samples from HFKs containing the empty LXSN vector by RT-PCR showed that it did not 
express the HPV-oncogenes while the HFK-16E6 and HFK-16E7 cell lines expressed the 
appropriate oncogene (Figure 7A).  We then tested the relative expression levels of 4 miRNAs, 
miR-363, miR-181a, miR-218, and miR-29a that were significantly affected in HPV-positive cell 
lines (Figure 6).  QRT-PCR analysis showed that miR-363 (upregulated in HPV-positive 
SCCHN cell lines compared to both HPV-negative SCCHN cell lines and NOK cells) was 
upregulated in the HFK-16E6 cell line, with p < .01, but not in the HFK-16E7 cell line (Figure 
7B).  Similarly, miR-181a, miR-218, and miR-29a (downregulated in HPV-positive SCCHN cell 
lines compared to both HPV-negative SCCHN cell lines and NOK cells) were downregulated in 
the HFK-16E6 cell line, with p < .01.  These miRNAs were either not affected or affected to a 
lesser extent in the HFK-16E7 cell line (Figure 7B).  These results showed that expression of the 
E6 oncogene of HPV-16 is associated with upregulation of miR-363 and downregulation of miR-
181a, miR-218, and miR-29a.   
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Figure 7: MiRNA expression in HFK cells expressing HPV-16 E6 or E7 
(A) RT-PCR analysis of the human papillomavirus (HPV)-16 E6 and E7 oncogene expression in the respective HFK 
cell line.  The UPCI:SCC90 cell line, known to express the HPV-16 E6 and E7 genes was used as a positive control.  
(B) QRT-PCR analysis of miR-363, miR-181a, miR-218, and miR-29a in the HFK cell lines.  No RT, no reverse 
transcriptase added.  Intensity values are relative to the HFK-LXSN cells, which were arbitrarily assigned a value of 
1 or -1.  The p values for the HPV-16 E6 and E7 expressing HFK cell lines compared to the HFK-LXSN cell line 
are indicated by ** (p<0.01) and * (p<0.05). 
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Because the expression of the HPV-16 E6 oncogene altered miRNA expression in the 
HFK cells, siRNA knockdown of HPV-16 E6 was done in the HPV-positive SCCHN cell line 
SCC2.  The qRT-PCR results showed that reduction in the levels of E6 were accompanied by a 
reduction in miR-363 levels (Figure 8).  These results suggest that E6 is involved in the 
upregulation of miR-363 in HPV-positive cell lines.   
 
 
 
 
Figure 8: qRT-PCR analysis of the HPV-positive SCCHN cell line SCC2 transfected with siRNA against 
HPV-16 E6 
(A) QRT-PCR analysis of HPV-16 E6 oncogene expression in the HPV-positive cell line SCC2 upon transfection 
with a negative control siRNA or with siRNA against E6.  (B) QRT-PCR analysis of miR-363 expression in cells 
transfected with a negative control siRNA or with siRNA against E6.  No RT, no reverse transcriptase added.  
Intensity values are relative to the SCC2 cells transfected with a negative control siRNA, which were arbitrarily 
assigned a value of -1.  The p values for the SCC2 + siRNA E6 cells compared to the SCC2 with the control siRNA 
are indicated by ** (p<0.01). 
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2.4 DISCUSSION 
HPV-positive and HPV-negative SCCHN have distinctly different clinical outcomes, and the 
expression and mutation status of important cell cycle control proteins are very different (Tran et 
al., 2007b; Vidal and Gillison, 2008).  Our data show that several cellular miRNAs are also 
differentially expressed in HPV-positive SCCHN cell lines as compared with HPV-negative 
SCCHN cell lines.  Many of these miRNAs were also found to be differentially expressed 
between the HPV-positive SCCHN cell lines and transformed oral keratinocytes lacking HPV 
DNA.  Similarly, expression of the high-risk HPV-16 E6 oncogene in HFKs was strongly 
associated with changes in miRNA expression similar to that seen in the HPV-positive SCCHN 
cell lines, whereas siRNA knockdown of HPV-16 E6 reversed this effect for miR-363.  These 
results suggest that HPV-16, and in particular the E6 oncogene, may be involved in altering the 
levels of several cellular miRNAs. 
Altered regulation of cellular miRNAs has been observed in several types of human 
cancers (Esquela-Kerscher and Slack, 2006; Lui et al., 2007; Tong and Nemunaitis, 2008) and 
upon oncogenic viral infections, including hepatitis B and C (Jiang et al., 2008), Epstein-Barr 
virus (Godshalk et al., 2008), human T-cell lymphotrophic virus 1 (Yeung et al., 2008), and 
HPV-16 (Lui et al., 2007; Wang et al., 2008; Wang et al., 2009a).  Recent studies have analyzed 
miRNA expression in SCCHN (Chang et al., 2008a; Kozaki et al., 2008; Ramdas et al., 2009; 
Tran et al., 2007a; Wong et al., 2008a; Wong et al., 2008b) and found that miRNA profiles in 
SCCHN are different compared to normal oral tissue.  However, currently there is no 
information available on differential miRNA expression between HPV-positive and HPV-
negative SCCHN.  Because HPV infection has been shown to play a significant role in the 
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etiology and prognosis of SCCHN (Tran et al., 2007b; Vidal and Gillison, 2008), we wanted to 
study the effect of HPV-16 infection on cellular miRNA dysregulation in SCCHN. 
Very few HPV-positive SCCHN cell lines have been described in the literature.  Of 4 
such cell lines that are available, we used 2 (UD-SCC-2 and UPCI:SCC90) to compare their 
miRNA expression profiles to that of 2 HPV-negative SCCHN cell lines (PCI13 and PCI30) by 
microarray analysis.  We further used the 2 additional HPV-16-positive SCCHN cell lines (UM-
SCC47 and 93-VU-147T) to validate the miRNA data obtained in the above comparison.  
MiRNA microarray analysis showed that 3 miRNAs (human miR-363 and miR-33, and rat miR-
497) were upregulated and 8 known and 1 predicted miRNAs were downregulated in the HPV-
positive SCCHN cell lines compared to the HPV-negative SCCHN cell lines (Table 3 and Figure 
6).  The miRNA microarray analysis was used as a screening tool, and the data were 
subsequently validated via qRT-PCR.  Similar to our current results, we have previously found 
that qRT-PCR analysis is much more sensitive than the miRNA microarrays and the fold-
difference in qRT-PCR assays is usually much greater (Martinez et al., 2008).  MiR-363 was 
specifically upregulated in HPV-16-positive SCCHN cell lines compared to the HPV-negative 
SCCHN cell lines and NOK cells (Table 3 and Figure 6A), suggesting a possible role of HPV-16 
in altering the levels of this miRNA.  Furthermore, experiments with HFKs showed that 
expression of the HPV-16 E6 oncogene increased the levels of miR-363 (Figure 7B) and siRNA 
knockdown of E6 reversed this effect (Figure 8).  Interestingly, miR-363 is part of the oncogenic 
miR-17~92 family of clusters, which is composed of 3 clusters of miRNAs, miR-17~92, miR-
106a~363, and miR-106b~25 and thought to have evolved through a series of deletions and 
duplications (Ventura et al., 2008).  Other members of this family of miRNA clusters have been 
implicated in cancers, including small cell lung cancer (Hayashita et al., 2005), B-cell lymphoma 
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(Ota et al., 2004), and T-cell leukemia (Landais et al., 2007).  MiRNAs in this family have 
similar or identical seed sequences (Ventura et al., 2008), and because the seed sequence of a 
mature miRNA contributes significantly to its specificity for its target mRNA (Bartel, 2004), it 
has been hypothesized that miRNAs in the miR-17~92 family may have similar functions 
(Ventura et al., 2008).  MiR-363 has identical seed sequences to miR-92-1, miR-92-2, and miR-
25 (Griffiths-Jones et al., 2008).  MiR-92-2 and miR-25 are also overexpressed in pancreatic, 
prostate, and stomach cancers (Volinia et al., 2006).  Recently, miR-25 has been shown to be 
upregulated in gastric cancers where it targets p57, an essential tumor suppressor (Kim et al., 
2009).  Because miR-363 and miR-25 have the same seed sequence, and miR-25 is involved in 
cell cycle disruption (Kim et al., 2009), it is possible that miR-363 may also be involved in the 
dysregulation of the cell cycle in HPV-associated SCCHN.  The qRT-PCR analysis for miR-
106a and miR-92a did not show any differences in expression between the HPV-positive and 
HPV-negative SCCHN cell lines (data not shown).  This is not surprising because many 
miRNAs in a cluster have independent promoters.  Landais et. al. (Landais et al., 2007) has 
shown that the miR-106a~363 cluster of miRNAs in mice is located downstream of the Kis2 
gene.  This gene has 3 different transcription start sites and it seems to encode the primary 
miRNAs of the miR-106a~363 cluster.  Also, the radiation leukemia virus is commonly 
integrated close to the Kis2 locus.  In mice, radiation leukemia virus-induced tumors had varied 
expression of miRNAs in the miR-106a~363 cluster, indicating that they may not be transcribed 
from the same promoter (Landais et al., 2007).  Also, in gastric cancer, miR-363 was shown to 
be downregulated compared to the normal tissue, whereas all of the other miRNAs in the miR-
106a~363 cluster were upregulated (Kim et al., 2009).  Thus, while miR-363 is overexpressed in 
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HPV-positive SCCHN cells compared to HPV-negative SCCHN cells, it is not surprising that we 
did not see a difference in expression of miR-106a and miR-92a between these cell lines. 
Our results also show downregulation of several miRNAs in HPV-associated SCCHN 
cell lines as compared to both HPV-negative SCCHN and NOK cell lines, including miR-155, 
miR-181a, miR-218, and miR-29a (Table 3, Figure 6, and Figure 7B).  We have recently 
demonstrated that the HPV-16 E6 oncogene downregulates miR-218 expression in HPV-16 
positive cervical carcinomas (Martinez et al., 2008).  Furthermore, we showed that miR-218 
targets LAMB3, and downregulation of miR-218 by the E6 oncogene results in overexpression of 
LAMB3 in cervical carcinoma cells (Martinez et al., 2008).  We found that expression of HPV-16 
E6 in HFK cells also reduced the levels of miR-218 (Figure 7B).  The downregulation of miR-
218 in both HPV-positive cervical and oropharyngeal cancer cell lines suggests that HPV-16 
may target cellular pathways common to these 2 types of cancers.  Although it is documented 
that p53 expression activates miR-34a (He et al., 2007) and miR-34a levels are reduced in HPV-
16-positive cervical cancer (Wang et al., 2009a), we did not find a statistically significant 
difference between miR-34a levels between HPV-positive and HPV-negative SCCHN cell lines.  
Whereas all the HPV-positive cell lines used in our study are p53 wild-type (wt), the HPV-
negative cell line PCI-13 has a p53 mutation while PCI-30 has wt p53 (Table 2).  There are 
several possible reasons for our observations of miR-34a.  For example, because the p53 
pathway is complex, it is possible that a single miRNA may be subject to multiple regulatory 
mechanisms. 
Viral infections have been implicated in altered cellular miRNA expression.  In human B 
lymphocytes infected with the Epstein-Barr virus, elevated levels of miR-155 help in viral 
persistence by reducing NF-κB signaling (Lu et al., 2008a).  It is intriguing that miR-155 was 
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found to be downregulated in the presence of HPV-16 in our studies (Table 3, Figure 6C, and 
Figure 7B).  There have been other studies on miRNA expression in head and neck cancers that 
have found miR-155 and miR-181a to be upregulated in oral cancer compared to normal oral 
tissue (Chang et al., 2008a; Wong et al., 2008a; Wong et al., 2008b).  However, when we 
compared HPV-positive and HPV-negative SCCHN cell lines, these miRNAs were 
downregulated in the presence of HPV-16 DNA.  Future studies should define the relationship 
between reduced levels of these miRNAs in HPV-positive SCCHN. 
Our studies showed that miR-181a and miR-29a were downregulated in HPV-positive 
SCCHN cells compared to HPV-negative SCCHN and NOK cells (Table 3, Figure 6D and 6F, 
and Figure 7B).  The levels of these 2 miRNAs also decreased upon expression of the HPV-16 
E6 oncogene in HFKs (Figure 7B), suggesting a role for E6 in downregulation of these miRNAs.  
The miR-181 family is known to be highly expressed in the brain (Miska et al., 2004) and is 
involved in thymocyte development (Chen et al., 2004), but its role in other tissues is less well-
understood.  Our data are the first to show a downregulation of miR-181a and miR-181b in 
HPV-positive SCCHN cell lines compared to HPV-negative SCCHN cell lines (Table 3, Figure 
6D, and Figure 7B).  Overexpression of miR-181a and miR-181b have been shown to induce 
apoptosis and inhibit growth and invasion in glioma cells (Shi et al., 2008).  Further studies on 
the roles of the miR-181 family may elucidate roles of these miRNAs in the different 
characteristics seen in HPV-positive and HPV-negative SCCHN.  MiR-29a has been shown to 
interact with viral proteins.  For example, miR-29a targets the HIV-1 Nef protein and interferes 
with viral replication (Ahluwalia et al., 2008).  MiR-29a also targets p85 and CDC42, which are 
negative regulators of p53 (Park et al., 2009b).  Because the HPV-16 E6 protein promotes the 
degradation of the p53 protein (zur Hausen, 2002), it is possible that the downregulation of miR-
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29a by E6 may further reduce p53 levels upon persistent HPV infection.  The precise role of 
HPV infection in cellular miRNA dysregulation, and the role of HPVs in SCCHN development, 
which also contributes to a better prognosis for these cancers as compared to their HPV-negative 
counterpart, will be the subject of future studies. 
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3.0  INCREASED EXPRESSION OF MICRORNA-363 IN HUMAN 
PAPILLOMAVIRUS-ASSOCIATED SQUAMOUS CELL CARCINOMA OF THE HEAD 
AND NECK TISSUES 
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3.1 INTRODUCTION 
Squamous cell carcinoma of the head and neck (SCCHN) is the most common head and 
neck malignancy and ranks sixth among cancers worldwide (Tran et al., 2007b).  There are more 
than 35,000 new cases of SCCHN in the United States and 500,000 new cases worldwide each 
year (Greenlee et al., 2001).  Although there have been advances in the detection and therapy of 
SCCHN, the prognosis still remains poor, with a 5-year survival of approximately 50 percent 
(Greenlee et al., 2001).  The majority of SCCHN cases are associated with heavy alcohol 
consumption and/or tobacco use, which over time induce mutations in essential genetic pathways 
that regulate the cell cycle (Tran et al., 2007b).  However, an emerging class of SCCHN has been 
associated with high-risk human papillomavirus (HPV), where up to 30 percent of SCCHN 
contain HPV-16 DNA, most often in the oropharynx region (oropharynx, base of tongue, and 
tonsil), and often occurs in individuals without the major risk factors of alcohol and tobacco use 
(D'Souza et al., 2007; Tran et al., 2007b). 
HPVs are small double-stranded DNA viruses that infect the basal lamina of the skin or 
mucous membranes (zur Hausen, 2002).  High-risk HPVs have been associated with several 
types of cancer, including cervical, anogenital, and oral cancers.  In HPV-associated cancers, 
expression of the E6 and E7 oncoproteins is essential for cellular transformation (Munger et al., 
2004).  The high-risk HPV E6 and E7 proteins target many cellular proteins to induce cellular 
transformation (for review on HPV oncogenes, see (Moody and Laimins, 2010)).  
HPV-positive and HPV-negative SCCHN have different characteristics, leading many to 
consider HPV-positive SCCHN a distinct tumor entity (Vidal and Gillison, 2008).  The tumor 
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suppressor protein p53 is mutated in up to half of oral cancers, but is rarely mutated in HPV-
positive SCCHN (Agrawal et al., 2011; Stransky et al., 2011; Vidal and Gillison, 2008).  Patients 
with HPV-positive oral tumors have a much better prognosis compared to HPV-negative 
SCCHN, with better response to chemotherapy, radiation, and surgery (Vidal and Gillison, 
2008).  It is also known that HPV-positive SCCHN cases have improved immune system 
activation to viral antigens (Albers et al., 2005) and have a lower likelihood of metastasis than 
patients with HPV-negative oral tumors (Fakhry and Gillison, 2006).  A recent study (Gillison et 
al., 2008) reported the association of HPV and oropharyngeal cancers with and without the 
established risk factors of alcohol and tobacco use, suggesting that HPV-positive and HPV-
negative SCCHN are discrete molecular, clinical, and pathological diseases.  Because of a recent 
increase in HPV-positive SCCHN cases (Chaturvedi et al., 2008) and their distinct clinical 
behavior, the molecular basis for the differences between HPV-positive and HPV-negative 
SCCHN is under intense investigation. 
Micro (mi) RNAs are small, endogenously encoded single-stranded RNAs that are most 
commonly associated with post-transcriptional negative regulation of gene expression (Bartel, 
2004).  Some miRNAs have been shown to function as tumor suppressors or oncogenes, and the 
dysregulation of such miRNAs have been observed in various cancers, including head and neck 
cancers (Childs et al., 2009; Esquela-Kerscher and Slack, 2006; Hui et al., 2010; Ramdas et al., 
2009; Tran et al., 2007a; Volinia et al., 2006; Wong et al., 2008a). 
We have previously reported differences in miRNA expression in HPV-positive and 
HPV-negative SCCHN cell lines, and miR-363 was found to be the most overexpressed miRNA 
in HPV-positive SCCHN cell lines (Wald et al., 2011).  In this study, we sought to investigate 
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whether miR-363 is also overexpressed in HPV-positive SCCHN tumors compared to the HPV-
negative SCCHN tumors in patients from the western Pennsylvania area. 
3.2 MATERIALS AND METHODS 
3.2.1 SCCHN Cell Lines 
Two SCCHN cell lines were used as positive and negative controls for HPV status and HPV 
gene expression analysis.  PCI-30 (gift from Dr. Theresa Whiteside, University of Pittsburgh 
Cancer Institute) is an HPV-negative SCCHN cell line and UPCI:SCC90 is an HPV-16-positive 
SCCHN cell line (previously described in (Wald et al., 2011)).  These cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (Lonza, Walkersville, MD) supplemented with 10% 
fetal bovine serum, 1% penicillin/streptomycin, and 2% L-glutamine at 37°C plus 5% CO2.   
3.2.2 SCCHN Tissues 
41 SCCHN tissues were obtained from patients according to Institutional Review Board protocol 
99-069.  Upon surgical removal, a portion of all tissues was sent to pathology for official tumor 
staging and the remainder of all tissues was flash frozen until further processing. 
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3.2.3 DNA Isolation 
DNA was isolated from all SCCHN tissues and cell lines using the DNeasy Blood & Tissue kit 
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
3.2.4 RNA Isolation 
Total RNA was isolated from all SCCHN tissues and cell lines using the Ultraspec RNA 
Isolation System (Biotecx, Houston, TX) according to the manufacturer’s protocol. 
3.2.5 PCR and RT-PCR 
HPV status of all SCCHN tissues was analyzed using the MY09/MY11 primer set, which 
amplifies a conserved region of the HPV L1 gene (Ferris et al., 2005).  The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was used as a loading control, using 5′-
CGACCACTTTGTCAAGCTCA-3′ as the forward primer and 5′-
AGGGGTCTACATGGCAACTG-3′ as the reverse primer, amplifying a 332-bp region.  All 
PCR reactions were performed using 20ng template DNA, 200µM of each deoxynucleoside 
triphosphate (dNTP), 0.5µM of each primer, and 0.5 units of Taq polymerase and the associated 
buffer (Promega, Madison, WI).  Thermocycler conditions for all PCR reactions were 94°C for 5 
minutes; 35 cycles of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30 seconds; and 
72°C for 10 minutes.  The PCR amplified DNA was visualized by agarose gel electrophoresis.  
HPV-positive samples were tested for HPV type by amplifying the HPV-16 gene.  HPV-16 E6 
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primers were forward 5′-AATGTTTCAGGACCCACAGG-3′ and 5′-
CAGCTGGGTTTCTCTACGTG-3′, amplifying a 454-bp region.   
RT-PCR was done on HPV-16 E6 and E7 oncogenes to show expression in HPV-positive 
SCCHN tumors.  The HPV-16 E6 gene was amplified using the primer set described above and 
the HPV-16 E7 gene was amplified using the forward primer 5′-
CATGGAGATACACCTACATTGCAT-3′ and the reverse primer 5′-
GAACAGATGGGGCACACAAT-3′, amplifying a 281-bp region.  cDNA synthesis was done 
using the iScript Select cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to the 
manufacturer’s protocol using random primers.  DNase I-treated RNA (60ng of total RNA) was 
used for each cDNA synthesis reaction, and the cDNA was PCR amplified for HPV-16 E6, 
HPV-16 E7, and GAPDH. 
3.2.6 Determination of HPV DNA and p16 Expression in Tumor Tissue 
Fluorescence in situ hybridization (FISH) for HPV-16 DNA was performed with a proprietary 
pan selective probe set (Dako Cytomation, Carpinteria, CA).  Immunohistochemical (IHC) 
evaluation of the remaining deparaffinized sections was performed using immunoperoxidase 
staining for p16 (p16INK4 mAb, BD Pharmingen, dilution 1:200) and scored semiquantitatively 
for each core.  Nuclear staining by HPV-16 FISH and diffuse p16 IHC (>80% cells) was 
considered HPV-positive. 
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3.2.7 Real-Time Quantitative Reverse Transcriptase PCR (qRT-PCR) 
Relative levels of miR-363 were measured using the TaqMan MicroRNA Reverse Transcription 
Kit and the TaqMan MicroRNA Assay (Applied Biosystems, Foster City, CA) and the iQ5 Real-
Time Thermocycler (Bio-Rad).  Twenty-five nanograms of total RNA was used for each 
reaction, and all reactions were performed in triplicate.  Assays were done according to the 
manufacturer’s instructions, and the miRNA levels were normalized to the RNU43 small 
nucleolar RNA levels.  Relative miR-363 expression was calculated using the 2-∆∆CT values 
(Livak and Schmittgen, 2001).  Statistical analysis of miR-363 qRT-PCR expression was done 
via a 2-tailed t test.   
3.3 RESULTS AND DISCUSSION 
3.3.1 HPV is Prevalent in Western PA SCCHN Cases 
We studied a cohort of 41 SCCHN patients treated at the University of Pittsburgh Cancer 
Institute between the years 2006 and 2009.  The clinical and demographic characteristics of the 
patients are detailed in Table 4 and summarized in Table 5.  Upon receipt, all tissues were tested 
for HPV positivity via PCR with the MY09/MY11 primers as described previously (Figure 9) 
(Wald et al., 2011).  Although HPV FISH was done for some SCCHN samples, DNA PCR was 
used for all samples because of its high sensitivity of amplifying HPV DNA and to complete the 
HPV testing on all samples.  Of the 41 SCCHN samples, 24 (59%) were HPV-positive and 17 
(41%) were HPV-negative.  Fifteen of the 18 samples tested for HPV via FISH were HPV-
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positive, confirming that testing for HPV via PCR has higher sensitivity than HPV testing via 
FISH.  All samples that were tested clinically for p16 (16 of the 24 HPV-positive samples) were 
positive for p16.  Only six HPV-negative SCCHN samples were tested for p16, two of which 
were p16 positive, indicating that some HPV-negative SCCHN samples had high p16 expression.  
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Table 4: Detailed demographics of SCCHN tissues 
Specimen Site TNM Stage Gender Race Age at diagnosis HPV status 
Tobacco 
history Alcohol history Status Metastasis 
          
Gum T1N0M0 Male Caucasian 78 HPV-negative never smoker never drinker Deceased cheek mucosa, mouth, tongue 
Cheek T2N1M0 Male Caucasian 68 HPV-negative former smoker current drinker Deceased 
cheek mucosa, 
lip, soft palate, 
oropharynx 
Mouth (1) T1N1M0 Male Caucasian 80 HPV-negative never smoker never drinker Alive none 
Mouth (2) T2N2CM0 Male Caucasian 56 HPV-16 former smoker former drinker Alive none 
Tongue (1) T3N2M0 Male Caucasian 64 HPV-16 current smoker current drinker Deceased mouth, lung 
Tongue (2) T3N2BM0 Male Caucasian 64 HPV-negative current smoker former drinker Deceased none 
Tongue (3) T4N2BM0 Female Caucasian 48 HPV-negative current smoker * current drinker * Deceased none 
Tongue (4) T4AN2CM0 Male Caucasian 65 HPV-negative former smoker current drinker Deceased none 
Vallecula T2BN2M0 Male African-American 51 HPV-16 never smoker never drinker Alive none 
Base of tongue (1) T1N2BM0 Female Caucasian 84 HPV-negative current smoker * current drinker Deceased none 
Base of tongue (2) T1N2BM0 Male Caucasian 50 HPV-16 current smoker * former drinker Alive none 
Base of tongue (3) T2N0 Female Caucasian 57 HPV-16 former smoker never drinker Deceased lymph node (tongue) 
Base of tongue (4) T2N0M0 Male Caucasian 60 HPV-16 former smoker never drinker Deceased none 
Base of tongue (5) T2N0M0 Male Caucasian 60 HPV-negative former smoker current drinker * Deceased base of tongue 
Base of tongue (6) T2N1M0 Male Caucasian 51 HPV-16 current smoker * former drinker Alive none 
Base of tongue (7) T2N1M0 Female Caucasian 82 HPV-negative current smoker current drinker * Alive lung 
Base of tongue (8) T2N2M0 Male Caucasian 70 HPV-16 unknown unknown Deceased recurrence - vallecula 
Base of tongue (9) T2N2BM0 Male Caucasian 62 HPV-16 never smoker never drinker Alive none 
Base of tongue (10) T2N2CM0 Male Caucasian 48 HPV-16 current smoker current drinker Deceased lymph nodes (head/face/neck) 
Base of tongue (11) T2N3M0 Male African-American 68 HPV-16 current smoker * current drinker Deceased lymph nodes (intrathoracic) 
Base of tongue (12) T3N0M0 Female Caucasian 59 HPV-negative never smoker never drinker Alive none 
Oropharynx (1) T2N0M0 Male Caucasian 48 HPV-negative current smoker former drinker Alive none 
Oropharynx (2) T4BN2BM0 Male Caucasian 54 HPV-negative former smoker current drinker Deceased 
tongue, lymph 
nodes 
(head/face/neck) 
mouth 
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Oropharynx (3) 
recurrent - 
stage 
unknown 
Male Caucasian 59 HPV-negative current smoker * current drinker * Alive 
primary - gum, 2 
recurrences 
oropharynx 
Tonsil (1) T1N1M0 Male Caucasian 46 HPV-16 never smoker current drinker Alive 
met via PET 
scan - Level II 
LN 
Tonsil (2) T2N0M0 Female Caucasian 54 HPV-16 unknown unknown Alive none 
Tonsil (3) T2N0M0 Male Caucasian 64 HPV-16 former smoker never drinker Alive recurrence - base of tongue 
Tonsil (4) T2N0M0 Male Caucasian 60 HPV-16 never smoker never drinker Alive none 
Tonsil (5) T2N1M0 Male Caucasian 49 HPV-16 snuff * current drinker Deceased 
bones in 
skull/face, lung, 
bones in 
pelvic/sacrum 
Tonsil (6) T2N2 Male Caucasian 50 HPV-16 former smoker never drinker Alive none 
Tonsil (7) T2N2M0 Male Caucasian 48 HPV-16 current smoker current drinker Deceased none 
Tonsil (8) T2N2AM0 Male Caucasian 61 HPV-16 former smoker former drinker Alive none 
Tonsil (9) T2N2BM0 Male Caucasian 50 HPV-16 current smoker current drinker Alive none 
Tonsil (10) T2N2BM0 Female Caucasian 56 HPV-16 current smoker * current drinker Alive none 
Tonsil (11) TXN2BM0 Female Caucasian 48 HPV-16 former smoker current drinker Alive none 
Tonsil (12) T2N2BM0 Female Caucasian 55 HPV-negative current smoker * current drinker * Alive none 
Tonsil (13) T2N2CM0 Male Caucasian 63 HPV-16 current smoker * current drinker * Alive none 
Tonsil (14) T2N3M0 Male Caucasian 49 HPV-16 current smoker * current drinker * Alive none 
Tonsil (15) T4N2BM0 Male Caucasian 65 HPV-negative current smoker * current drinker * Deceased none 
Tonsil (16) T4N3M0 Male Caucasian 65 HPV-negative current smoker * former drinker Deceased none 
Tonsil (17) T4AN2BM0 Male Caucasian 57 HPV-negative current smoker current drinker Deceased none 
Abbreviations: * unknown if quit 
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Table 5: Summary of SCCHN tissue characteristics 
 HPV-16-positive HPV-negative 
Age, mean (SD) 55.6 (7.1) 64.2 (11.2) 
Gender, n (%) 
   Males 
   Females 
 
20 (83%) 
4 (17%) 
 
12 (71%) 
5 (29%) 
Tumor location 
   Mouth* 
   Tongue 
   Vallecula 
   Base of tongue 
   Oropharynx 
   Tonsil 
 
1 
1 
1 
8 
0 
13 
 
3 
3 
0 
4 
3 
4 
Tumor stage 
   T1NXMX 
   T2NXMX 
   T3NXMX 
   T4NXMX 
   Unknown 
 
2 
21 
1 
0 
0 
 
3 
5 
2 
6 
1 
* Mouth samples include mouth, gum, and cheek. 
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Figure 9: HPV status in SCCHN tissues 
PCR analysis of all SCCHN tissues using the MY09/MY11 primer set to detect HPV positivity.  SCC90, an HPV-
positive SCCHN cell line control.  PCI30, an HPV-negative SCCHN cell line control. 
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All HPV-positive samples were subsequently tested for HPV type via DNA PCR for the 
HPV-16 and HPV-18 E6 gene.  All HPV-positive samples were found to contain HPV-16 DNA 
(Figure 10A).  All of the HPV-positive tumor tissues were found to express the HPV-16 E6 and 
E7 oncogenes as determined by RT-PCR (Figure 10B).  
 
 
Figure 10: HPV-16 PCR and RT-PCR in SCCHN tissues 
(A) PCR of HPV-16 E6 gene in HPV-positive SCCHN tissues.  (B) RT-PCR of HPV-16 E6 and E7 in HPV-positive 
SCCHN tissues.  SCC90, an HPV-16-positive SCCHN cell line positive control; PCI30, an HPV-negative SCCHN 
cell line negative control; No RT, no reverse transcriptase added (used SCC90 sample).  
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As expected, the site with the highest HPV positivity rate (via PCR) in our cohort was the 
tonsil, with 76 percent being HPV-positive, followed by tumors of the base of tongue, with 67 
percent being HPV-positive (Table 5).  The HPV-positive SCCHN cases of the tonsil and base of 
tongue represented approximately 88 percent of all HPV-positive tumors.  The HPV-negative 
SCCHN cases had a more even distribution of the tumor sites, including the base of tongue, 
oropharynx, tonsil, mouth, and tongue (Table 5).  The average age at diagnosis for patients with 
HPV-positive SCCHN was 55.6 years, or approximately nine years younger than for patients 
with HPV-negative SCCHN tumors, similar to other studies (Chaturvedi et al., 2008; Tran et al., 
2007b).  Ninety-six percent of HPV-positive SCCHN cases were classified as T1 or T2, whereas 
only 50 percent of HPV-negative SCCHN cases manifested small primary tumors (Table 5).  
These results are consistent with demographics and clinopathologic features reported for HPV-
positive disease, supporting the reflection of our cohort with those reported in the literature 
(Chaturvedi et al., 2008).   
3.3.2 MicroRNA-363 is Overexpressed in HPV-Positive SCCHN Tissues 
We have previously reported that several miRNAs have altered expression in HPV-positive 
SCCHN cell lines compared to HPV-negative SCCHN cell lines, including the upregulation of 
miR-363 and downregulation of miR-181a, miR-218, and miR-29a (Wald et al., 2011).  In that 
study, we also showed that differential expression of these miRNAs was dependent upon the 
expression of the HPV-16 E6 oncogene (Wald et al., 2011).  We carried out qRT-PCR analysis 
of miR-363 expression in the HPV-positive and HPV-negative SCCHN samples.  HPV-positive 
SCCHN samples expressed higher miR-363 levels compared to the HPV-negative SCCHN 
samples, with p<0.01 (Figure 11).  These data are consistent with those obtained with the 
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SCCHN cell lines (Wald et al., 2011), indicating that our work with SCCHN cell lines has 
clinical relevance.  
 
 
Figure 11: MicroRNA-363 expression in SCCHN tissues 
QRT-PCR analysis of miR-363 in HPV-positive and HPV-negative SCCHN tissues.  Black bars, HPV-16-positive 
SCCHN samples; gray bars, HPV-negative SCCHN samples.  Intensity values are relative to the HPV-negative 
SCCHN sample with the lowest miR-363 expression, which was arbitrarily assigned a value of 1.  The p-value for 
the HPV-positive samples compared to the HPV-negative samples is indicated by ** (p<0.01).  BOT, base of 
tongue; no RT, no reverse transcriptase added. 
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MiR-363 has recently been shown to be overexpressed in HPV-positive pharyngeal 
squamous cell carcinoma (PSCC) tissues in a Danish population (Lajer et al., 2011).  Lajer and 
colleagues found miR-363 to be the most overexpressed miRNA in 9 HPV-positive PSCC 
compared to 11 HPV-negative PSCC (Lajer et al., 2011).  Interestingly, in their study, PSCC had 
an HPV-positivity rate of 42 percent, while OSCC (oral squamous cell carcinoma) had an HPV-
positivity rate of only 3 percent.  The PSCC tumors came from the tonsil, base of tongue, and 
other pharyngeal sites, whereas the OSCC samples came from the tongue, bucca, floor of mouth, 
gingiva, and other oral cavity sites (Lajer et al., 2011).  This supports our finding that HPV-
positivity rates are highest among the tonsil and base of tongue.   
The association between high miR-363 expression in HPV-positive head and neck 
cancers can be further explored for possible targets of therapeutic intervention or biomarkers for 
prognosis.  
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4.0  MICRORNA-363 TARGETS MYSOIN 1B AND INCREASES THE 
PROLIFERATION AND COLONY FORMATION OF SCCHN CELL LINES 
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4.1 INTRODUCTION 
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer in the 
United States (Jemal et al., 2010) and one of the leading cancers in developing countries (Parkin 
et al., 1999).  Along with the well-established risk factors of alcohol and tobacco use, infection 
with high-risk human papillomavirus (HPV), most notably type-16, has emerged as a significant 
risk factor for SCCHN (Chaturvedi et al., 2008; Tran et al., 2007b).  Characteristics of HPV-
positive SCCHN differ from those of HPV-negative SCCHN, supporting the notion that these 
cancers should be classified as distinct tumor entities (Vidal and Gillison, 2008).  HPV-positive 
SCCHN most often occurs in the oropharynx region (upwards of 50 percent or more), and is 
diagnosed in younger patients compared to HPV-negative SCCHN.  Moreover, SCCHN tumors 
that are HPV-positive have infrequent p53 mutations while up to half of HPV-negative SCCHN 
tumors have p53 mutations (Vidal and Gillison, 2008).  Patients with HPV-positive SCCHN 
tumors respond better to chemotherapy, radiation, and surgery, and have an overall 60 percent 
reduction in death from SCCHN than patients with HPV-negative SCCHN tumors (Tran et al., 
2007b; Vidal and Gillison, 2008). 
We have previously shown that micro (mi) RNA profiles in HPV-positive SCCHN cell 
lines differ from HPV-negative SCCHN cell lines, and some miRNAs are dysregulated as a 
direct result of the HPV-16 E6 and E7 oncogene expression (Wald et al., 2011).  Furthermore 
miR-363, which was the most highly overexpressed miRNA in HPV-positive SCCHN cell lines 
compared to HPV-negative SCCHN cell lines, also shows this trend in a subset of HPV-positive 
and HPV-negative SCCHN tumors from the western Pennsylvania population.  In this study, we 
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sought to identify the possible mechanisms by which miR-363 may contribute to SCCHN 
pathogenesis.  We show that miR-363 targets myosin 1b, which reduces the migratory ability of 
SCCHN cells.  Additionally, miR-363 increases the proliferation and colony formation of 
SCCHN cells. 
4.2 MATERIALS AND METHODS 
4.2.1 Cell Culture and Transfections 
The HPV-negative SCCHN cell line PCI-30 was grown in Dulbecco’s modified Eagle’s medium 
(Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin, and 2% L-glutamine at 37°C in the presence of 5% CO2.  The HPV-
negative SCCHN cell line JHU-028 was grown in Roswell Park Memorial Institute medium 
(Lonza) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 2% L-
glutamine at 37°C in the presence of 5% CO2.   
HPV-negative SCCHN cells PCI-30 or JHU-028 (1.5 x 105) were seeded in 6-well plates 
in antibiotic-free media.  The following day, cells were transfected with 50 nM pre-miR (Applied 
Biosystems, Foster City, CA) or 50 nM siRNA against MYO1B (ThermoFisher Scientific, San 
Jose, CA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and Opti-mem (Gibco, Grand 
Island, NY).  A FAM-labeled negative control pre-miR (Applied Biosystems) or the Block-it 
fluorescent oligo (Invitrogen) was used as the negative controls and to measure transfection 
efficiency.  Cells were harvested 48 hours after transfection and RNA and proteins were isolated 
for various assays. 
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4.2.2 RNA Isolation 
Total RNA was isolated from cell lines using the Ultraspec RNA Isolation System (Biotecx, 
Houston, TX) according to the manufacturer’s instructions. 
4.2.3 Quantitative Real Time RT-PCR 
To confirm the efficiency of miR-363 transfections, miRNA expression was measured using the 
TaqMan MicroRNA Reverse Transcription Kit and the TaqMan MicroRNA Assays (Applied 
Biosystems) and the Real-Time Thermocycler iQ5 (Bio-Rad, Hercules, CA).  Total RNA (50 µg) 
was used for each reaction, and all of the reactions were performed in triplicate according to the 
manufacturer’s instructions.  MiRNA levels were normalized to small nucleolar RNU43 levels 
and relative expression was calculated using the 2-∆∆CT values (Livak and Schmittgen, 2001).  
Gene expression (mRNA) levels were measured using the iScript One-Step RT-PCR Kit with 
SYBR Green (Bio-Rad).  The MYO1B gene was amplified using the forward primer 5′-
GGTCTGGTGTGGAGGTCCTA-3′ and the reverse primer 5′-CGTTGCTTCCTCAGGTCTTC-
3′, amplifying a 127 bp region.  The MYO1B mRNA levels were normalized to the GAPDH 
mRNA levels, using the forward primer 5′-CAGCCTCAAGATCATCAGCA-3′ and the reverse 
primer 5′-TGTGGTCATGAGTCCTTCCA-3′ which amplifies a 106 bp region.  DNase-I-treated 
total RNA (50 ng) was used for each reaction, and all the reactions were done in triplicate.  
MYO1B mRNA was normalized to GAPDH, and the relative expression levels were calculated 
using the 2-∆∆CT values (Livak and Schmittgen, 2001) 
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4.2.4 Spectral Counting Proteomics 
The HPV-negative SCCHN cell line PCI-30 was transfected as described above with a negative 
control pre-miR or pre-miR-363.  After 48 hours, cells were lysed in 50 mM Tris-HCl, pH 7.4, 
0.5% SDS, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride 
(PMSF) by boiling for 10 minutes, cooling to ambient temperature and then sonicating three 
times.  Protein quantitation was performed using the BCA Assay (Pierce, Rockford, IL) and 30 
mg of protein was loaded onto a 10% Bis-Tris gel and run until the proteins entered the stacking 
portion of the gel.  The gel bands for each sample were excised and diced into approximately 1 
mm2 sections and destained in 25 mM NH4HCO3/50% acetonitrile (ACN) with shaking.  Gel 
bands were dehydrated by addition of neat ACN and then dried in a 37°C incubator.   
Proteins in the gel bands were reduced in 25 mM NH4HCO3, 10 mM dithiothreitol (DTT) 
at 56°C for 1 hour followed by dehydration with ACN as before, and then alkylation was carried 
out in 25 mM NH4HCO3, 55 mM iodoacetamide for 45 minutes in the dark at ambient 
temperature followed by dehydration.  Gel bands were rehydrated with trypsin (Promega, 
porcine sequencing grade, 20 ng/ml) on ice for 45 minutes.  Supernatant was removed and the 
gel bands were washed once with 500 µl of 25 mM NH4HCO3, and then the gel bands were 
covered with 25 mM NH4HCO3, (~100 µl) and incubated at 37°C overnight.  The digest solution 
was transferred into a clean microcentrifuge tube and peptides were extracted from the gel pieces 
with sonication in a water bath for 10 minutes in 75 µl of 50% ACN/5% formic acid.  The 
supernatant was removed and added to the previous solution and this was repeated two additional 
times.  The combined extract was lyophilized to dryness and stored at -80°C until analysis. 
 64 
Samples were analyzed by nanoflow reverse-phase liquid chromatography (Ultimate 
3000, Dionex, Sunnyvale, CA) coupled online via electrospray ionization to a hybrid linear ion 
trap-Orbitrap mass spectrometer (LTQ-Orbitrap, ThermoFisher Scientific, San Jose, CA).  Five 
replicate injections of peptide extracts were resolved on 100 µm i.d. by 360 µm o.d. by 200 mm 
long fused silica capillary columns (Polymicro Technologies, Phoenix, AZ) slurrypacked in-
house with 5 µm, 300 Å pore size C-18 silica-bonded stationary phase (Jupiter, Phenomenex, 
Torrance, CA).  After sample injection, peptides were eluted from the column using a linear 
gradient of 2% mobile phase B (0.1% formic acid in ACN) to 40% mobile phase B over 125 
minutes at a constant flow rate of 200 nl/minutes followed by a column wash consisting of 95% 
B for an additional 30 minutes at a constant flow rate of 400 nl/minute.  The column was then re-
equilibrated in mobile phase A (0.1% formic acid in water) for 20 minutes prior to the next 
injection.  Eluting peptides were ionized using an electrospray voltage of 1.8 kV and analyzed in 
the LTQ-Orbitrap MS which was configured to collect high resolution (R=60,000 at m/z 400) 
broadband mass spectra (m/z 375-1800) from which the seven-most abundant peptide molecular 
ions dynamically determined from the MS scan were selected for tandem MS using a relative 
collision-induced dissociation (CID) energy of 30%.  Dynamic exclusion was utilized to 
minimize redundant selection of peptides for CID. 
Peptide identifications were obtained by searching the LC-MS/MS data utilizing 
SEQUEST (BioWorks, v3.2, ThermoFisher Scientific) on a 72-node Beowulf cluster against a 
UniProt-derived human proteome database (11/2009 release) obtained from the European 
Bioinformatics Institute (EBI) using the following parameters: trypsin (KR); full enzymatic 
cleavage; two missed cleavage sites; 20 ppm peptide mass tolerance peptide tolerance, 0.5 amu 
fragment ion tolerance; and variable modifications for methionine oxidation (m/z 15.99492) and 
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cysteine carboxyamidomethylation (m/z 57.02146).  Resulting peptide identifications were 
filtered according to specific SEQUEST scoring criteria: delta correlation (DCn) 3 0.08 and 
charge state dependent cross correlation (XCorr) scores of 3 1.9 for [M+H]1+, 3 2.2 for [M+H]2+, 
and 3 3.5 for [M+H]3+.  These criteria resulted in a false discovery rate of <1% for all peptides 
identified as determined by searching the data against a decoy human database where the protein 
sequences were reversed.  The differences in protein abundance between the samples were 
derived by spectral counting.  
4.2.5 Western Blotting 
Proteins (25 µg) from total cell lysates from the HPV-negative SCCHN cell line PCI-30 
transfected with pre-miR-363 were separated on a 10% SDS polyacrylamide gel and transferred 
to Immobilion-P PVDF membrane (Millipore, Billerica, MA).  The membrane was incubated 
with a primary rabbit polyclonal antibody against MYO1B (Santa Cruz Biotechnology, Santa 
Cruz, CA), and subsequently incubated with a 1:10,000 dilution of the secondary anti-rabbit 
horseradish peroxidase antibody (Amersham Biosciences, Piscataway, NJ).  Blots were 
visualized using chemiluminescence with the ECL Plus Western Blotting Detection Reagents 
(Amersham Biosciences), followed by film exposure.  A murine monoclonal antibody against 
GAPDH (Chemicon, Billerica, MA) was used to show equal sample loading.  
4.2.6 Cloning of the MYO1B 3′ UTR into pMiR-Report Luciferase Vector 
The MYO1B 3′ UTR (1429 bp) was PCR amplified from the HPV-positive SCCHN cell line 
SCC90 using the forward primer 5′-GGACTAGTAACCGTCTCCTTGAAGTTGC-3′ and the 
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reverse primer 5′-GGAAGCTTGGCACAAGGCAAGAAGAATC-3′, amplifying a 1,725 bp 
region.  These primers were designed with an added SpeI restriction site on the forward primer 
and a HindIII restriction site on the reverse primer to aid in directional cloning.  PCR products 
were separated on a 1% agarose gel, and the DNA was isolated using the QIAquick Gel 
Extraction Kit (Qiagen, Valencia, CA).  Three micrograms of each of the purified PCR products 
and the pMiR-Report luciferase vector (Applied Biosystems) were digested with SpeI and 
HindIII at 37°C for two hours.  The digested DNA was separated on a 1% agarose gel, purified 
using the QIAquick Gel Extraction Kit (Qiagen), and quantified using the Nanodrop.  The 
digested MYO1B 3′ UTR and pMiR-Report vector were ligated at a 1:3 (vector:insert) ratio at 
16°C for 16 hours.  DNA was precipitated and the ligated plasmid was electroporated into 
competent DH5α cells.  After a one-hour recovery, cells were plated on LB + ampicillin plates 
and incubated at 37°C overnight.  Ten colonies were patched on LB + ampicillin plates and 
incubated at 37°C overnight.  A lysates gel was run to determine the presence of the pMiR-
Report:MYO1B 3′ UTR plasmid.  Selected colonies that contained the plasmid were grown in 
LB broth + ampicillin at 37°C overnight and the pMiR-Report:MYO1B 3′ UTR plasmids were 
extracted using the Wizard Plus Minipreps DNA Purification System (Promega, Madison, WI).  
The plasmids were subsequently digested with HindIII and BamHI for 2 hours at 37°C and run 
on a 1% agarose gel to confirm the insertion of the appropriate DNA fragment. 
4.2.7 Luciferase Assays 
HPV-negative JHU-028 SCCHN cells (10,000 cells per well) were seeded in a 96-well plate in 
antibiotic free media.  After 24 hours, cells were transfected using Lipofectamine 2000 
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(Invitrogen) and Opti-mem (Gibco) with the following nucleic acids: (A) 0.1 µg pMiR-Report + 
2.5 ng phRL-TK, (B) 0.1 µg pMiR-Report + 2.5 ng phRL-TK + 50 nM negative pre-miR, (C) 
0.1 µg pMiR-Report + 2.5 ng phRL-TK + 50 nM pre-miR-363, (D) 0.1 µg pMiR-
Report:MYO1B 3′ UTR + 2.5 ng phRL-TK, (E) 0.1  µg pMiR-Report:MYO1B 3′ UTR + 2.5 ng 
phRL-TK + 50 nM negative pre-miR, or (F) 0.1 µg pMiR-Report:MYO1B 3′ UTR + 2.5 ng 
phRL-TK + 50 nM pre-miR-363.  After 48 hours, luciferase activity was measured using the 
Dual-Luciferase Reporter Assay (Promega) and the Synergy 2 Luminometer. 
4.2.8 Transwell Migration Assays 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 or an siRNA 
against MYO1B as described above.  Forty-eight hours after transfection, cells were harvested 
and re-seeded into 24-well Transwell inserts, 8 µm pore size (Corning) in media depleted of 
serum.  The bottom chambers of the transwell plate were filled with media containing 20% 
serum to serve as a chemoattractant.  Transwells were stained with 0.1% crystal violet at 1, 3, 
and 5 hours post-plating and the cells were counted and photographed under a microscope.  The 
mean of eight fields from four separate assays was used to determine the average number of 
migratory cells. 
4.2.9 Apoptosis Assay 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 as described 
above.  Forty-eight hours after transfection, live cells, dead cells, and apoptotic cells were 
analyzed using the AlexaFluor 488 Annexin V/Dead Cell Apoptosis Kit with AlexaFluor 488 
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annexin V and PI for Flow Cytometry (Invitrogen) according to the manufacturer’s instructions 
on the BD FACS Canto (BD Biosciences, San Jose, CA). 
4.2.10 Cell Cycle Analysis by Flow Cytometry 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 as described 
above.  Forty-eight hours after transfection, cells were harvested and fixed in 70% ethanol 
overnight at 4°C.  Subsequently, the cells were washed once with 1X PBS and stained with 
propidium iodide for four hours and subjected to flow cytometry using the BD FACS Canto (BD 
Biosciences). 
4.2.11 MTT Assay 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 as described 
above.  Twenty-four hours post-transfection, cells were harvested and re-seeded at 2,000 cells 
per well of a 96-well plate.  After an additional 24 hours (48 hours post-transfection), cells were 
incubated with 20 µl of the MTT reagent (5mg/ml) at 37°C for 3 hours.  Subsequently, growth 
media and MTT reagent were removed from the wells, and 100 µl dimethyl sulfoxide was added 
and the plate was incubated at 37°C for 5 minutes on a shaker.  Absorbance was immediately 
measured at 490 nm. 
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4.2.12 Cell Counting 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 as described 
above.  Cells were harvested and counted at 0, 24, 48, and 72 hours post-transfection.  The mean 
of three wells of cells (per condition) was used to determine the average number of live cells.  
The number of live cells is relative to the zero hour time-point, which was set at 100%. 
4.2.13 In-vitro Wound Healing Assay 
The HPV-negative SCCHN cell line JHU-028 was transfected with pre-miR-363 as described 
above.  After 24 hours, the transfected cells were harvested and re-seeded to confluency in a 24-
well plate.  After an additional 24 hours (48 hours post-transfection), a scratch/wound was made 
using a sterile pipet tip that cleared ~500 µm wide gap in the confluent cells.  The wound width 
was measured and photographed every four hours until closed. 
4.2.14 Colony Formation Assay 
The HPV-negative SCCHN cell line PCI-30 was transfected with pre-miR-363 as described 
above.  Cells were harvested forty-eight hours post transfection and re-suspended at 20,000 
cells/ml in 0.3% agarose/media solution.  Two milliliters of the cell suspension was plated on top 
of 2 ml of solidified 0.5% agarose/media solution in a 6-well plate.  The 0.3% agarose/media/cell 
suspension was incubated at room temperature for one hour to allow the agarose to solidify, and 
then the 6-well plate was incubated at 37°C in 5% CO2.  Every two days, 500 µl of media was 
added to each well to prevent the gel from drying.  After 21 days, cells were stained with 0.5% 
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crystal violet and visualized under a dissecting microscope.  The mean number of colonies of 
three wells of a six-well plate was used to determine the average number of colonies formed per 
condition. 
4.3 RESULTS 
4.3.1 MicroRNA-363 Targets Myosin 1B in HPV-Positive SCCHN 
Since a miRNA can potentially regulate dozens of genes (Lim et al., 2005), we used gene 
expression profiling data (Martinez et al., 2007), spectral counting proteomics, and 
computationally predicted miRNA target databases to identify the potential gene target(s) of 
miR-363 in SCCHN.  Since we have previously shown that miR-363 is overexpressed in HPV-
positive SCCHN compared to HPV-negative SCCHN ((Wald et al., 2011) and unpublished data), 
the list of computationally predicted targets of miR-363 was compared with genes down-
regulated in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) compared to HPV-
negative OPSCC (Martinez et al., 2007), and with proteins downregulated by more than two-fold 
in HPV-negative SCCHN cells overexpressing miR-363 compared to HPV-negative SCCHN 
cells expressing a negative control miRNA. 
The HPV-negative SCCHN cell line PCI-30 had 35 proteins downregulated by at least 50 
percent upon exogenous overexpression of miR-363 compared to the same cell line expressing a 
negative control miRNA (Table 6).  These proteins were considered potential miR-363 targets 
from the proteomics data, along with the 150 downregulated genes in HPV-positive OPSCC 
compared to HPV-negative OPSCC that were identified in a previously published study 
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(Martinez et al., 2007), for a total of 185 potential miR-363 targets.  Interestingly, only the 
myosin 1b gene was found to be similarly downregulated between the proteomics and gene 
expression data. 
 
Table 6: Proteins downregulated in cells overexpressing miR-363 via spectral counting proteomics 
Protein 
Number of peptides identified 
in PC1-30 + neg control 
Number of peptides identified 
in PC1-30 + miR-363 Ratio 
Isoform 1 of Myosin-Ic 26 52 0.50 
Enoyl-CoA hydratase, 
mitochondria 11 23 0.49 
Isoform Alpha-3B of Integrin 
alpha-3 8 17 0.49 
Peroxisomal multifunctional 
enzyme type 2 7 15 0.48 
Isoform A of Bifunctional 3'-
phosphoadenosine 5'-
phosphosulfate synthetase 2 4 9 0.47 
Isoform Alpha of Signal 
transducer and activator of 
transcription 1-alpha/beta 13 28 0.47 
Isoform 1 of Hepatocyte growth 
factor-regulated tyrosine kinase 
substrate 3 7 0.47 
Isoform 1 of Myosin-Ib 3 7 0.47 
CAAX prenyl protease 1 
homolog 3 7 0.47 
ADP/ATP translocase 2 10 22 0.47 
Guanine nucleotide-binding 
protein G(k) subunit alpha 3 7 0.47 
Ras-related protein Ral-A 3 7 0.47 
Acetyl-CoA acetyltransferase, 
mitochondrial 10 22 0.47 
60S ribosomal protein L27 3 7 0.47 
Protein transport protein 
Sec23A 3 7 0.47 
Isoform 1 of Myb-binding 
protein 1A 3 7 0.47 
Isoform 1 of Arylacetamide 
deacetylase-like 1 12 27 0.45 
Splicing factor 3B subunit 1 6 14 0.45 
Isoform 1 of Neural cell 
adhesion molecule L1 5 12 0.44 
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Isoform 1 of ATPase family 
AAA domain-containing 
protein 3A 5 12 0.44 
Isoform 2 of Microtubule-actin 
cross-linking factor 1, isoforms 
1/2/3/5 7 17 0.43 
Isoform 1 of Nuclear pore 
complex protein Nup155 3 8 0.41 
Aconitate hydratase, 
mitochondrial 3 8 0.41 
Probable ATP-dependent RNA 
helicase DDX47 3 8 0.41 
Protein tyrosine phosphatase-
like protein PTPLAD1 3 8 0.41 
FACT complex subunit SPT16 7 18 0.41 
Isoform 1 of Cytoplasmic 
FMR1-interacting protein 1 4 11 0.39 
Isoform 1 of MAP7 domain-
containing protein 1 3 9 0.37 
Tyrosine-protein phosphatase 
non-receptor type 1 5 16 0.33 
Isoform 1 of Fragile X mental 
retardation syndrome-related 
protein 1 4 13 0.33 
Interferon-induced protein with 
tetratricopeptide repeats 1 3 12 0.28 
Guanine nucleotide-binding 
protein G(i), alpha-1 subunit 4 16 0.27 
Isoform 1 of CUB domain-
containing protein 1 3 13 0.26 
Inositol 1,4,5-trisphosphate 
receptor type 3 5 21 0.26 
Isoform 3 of Ribosome-binding 
protein 1 5 25 0.22 
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The 35 proteins from Table 6 and 150 downregulated genes from our previous study 
(Martinez et al., 2007) were cross-referenced with computationally predicted miR-363 targets 
obtained from the miRanda and TargetScan databases.  This cross-comparison resulted in six 
potential targets based upon proteomics data and ten potential targets based upon the gene 
expression data, with one potential miR-363 target in common, myosin 1b (MYO1B, Figure 12).    
 
 
 
 
 
Figure 12: Venn diagram of potential miR-363 targets 
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The 3′ UTR of MYO1B contains two predicted binding sites for miR-363, and since 
MYO1B expression at both the mRNA and protein levels was reduced upon miR-363 
overexpression (Figure 13), it was considered a likely target of miR-363.   
 
 
 
Figure 13: MYO1B expression is reduced upon miR-363 expression 
HPV-negative SCCHN cell line PCI30 transfected with either a negative control miRNA or miR-363.  (A) qRT-
PCR for MYO1B at mRNA level.  (B) Western blot for MYO1B at protein level.  The p value for PCI30 + miR-363 
compared to PCI30 + neg. is indicated by ** (p < 0.01). 
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To test whether MYO1B was a direct target of miR-363, we cloned the 3′ UTR of 
MYO1B downstream of the firefly luciferase gene in the pMiR-Report vector.  A dual luciferase 
assay, where the firefly luciferase was normalized to the renilla luciferase, showed that the firefly 
luciferase activity was reduced when miR-363 was overexpressed but not when a control 
miRNA that has no binding sites in the MYO1B 3′ UTR was expressed (Figure 14).  These 
results suggest that miR-363 binds directly to the 3′ UTR of MYO1B and represses its 
expression. 
 
 
Figure 14: MYO1B is a direct target of miR-363 in SCCHN 
Dual luciferase assay of HPV-negative SCCHN cells transfected with reporter vectors with or without the MYO1B 
3′UTR cloned downstream of firefly luciferase. The p value for pMiR-Report-MYO1B + miR-363 compared to 
pMiR-Report-MYO1B or pMiR-Report-MYO1B + miR-363 compared to pMiR-Report-MYO1B + negative 
miRNA is indicated by ** (p < 0.01). 
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4.3.2 MicroRNA-363 Reduces the Migratory Ability of HPV-Negative SCCHN Cells 
Since myosin proteins are associated with cellular migration amongst other functions (Edgar et 
al., 1996; Evangelista et al., 2000), we wished to investigate the effect of miR-363 on cellular 
migration.  Transwell migration assays showed that there was a significant decrease in the 
number of migratory HPV-negative SCCHN cells when miR-363 was overexpressed compared 
to the same cells that do not express miR-363 (Figure 15).  Since miR-363 targets MYO1B in 
SCCHN (Figure 14) and MYO1B is involved in cell migration (Edgar et al., 1996; Evangelista et 
al., 2000), we wanted to test whether reduction in MYO1B levels directly reduce cell migration.  
Knockdown of MYO1B via siRNA in HPV-negative SCCHN cells showed reduced cell 
migration compared to cells expressing a negative control siRNA (Figure 16).  These results 
indicate that high miR-363 expression (which would reduce MYO1B levels) as well as reduction 
in MYO1B levels by siRNA knockdown reduce cell migration (Figures 15 and 16). 
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Figure 15: MiR-363 reduces the migratory ability of HPV-negative SCCHN cells 
HPV-negative SCCHN cell line JHU-028 transfected with either a negative control miRNA or miR-363. (A) 
Transwell migration pictures at specified time points.  (B) Graph of migratory cells.  The p value for cells expressing 
miR-363 compared to cells expressing a negative miRNA is indicated by ** (p < 0.01). 
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Figure 16: siRNA knockdown of MYO1B reduces cell migration in HPV-negative SCCHN cells 
HPV-negative SCCHN cell line JHU-028 transfected with either a negative control miRNA or miR-363.  (A) qRT-
PCR of MYO1B expression post-transfection.  (B) Graph of migratory cells.  (C) Transwell migration pictures.  The 
p value for cells expressing miR-363 compared to cells expressing a negative miRNA is indicated by ** (p < 0.01). 
 
4.3.3 MicroRNA-363 Increases Proliferation of HPV-Negative SCCHN Cells 
In order to determine the functional role of miR-363 in SCCHN, we carried out apoptosis, cell 
cycle, and proliferation assays.  We observed no difference in the apoptosis of HPV-negative 
SCCHN cells (JHU-028 and PCI-30) overexpressing miR-363 compared to cells lacking miR-
363 expression (data not shown).  There was a slight, but not statistically significant, increase in 
the percentage of cells in the S-phase of the cell cycle when HPV-negative SCCHN cells (JHU-
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028 and PCI-30) overexpressed miR-363 compared to the same cells expressing a negative 
control miRNA (data not shown).  However, miR-363 overexpression in HPV-negative SCCHN 
cells (JHU-028) increased the proliferation capacity of these cells as measured via MTT assay 
and cell counting (Figure 17).  Furthermore, growth of miR-363-transfected cells in serum-
depleted media either had the same effect as cells grown in the normal media, or exacerbated the 
effect seen in cells grown in the normal media (Figure 17). 
 
Figure 17: MicroRNA-363 increases the proliferation of HPV-negative SCCHN cells 
HPV-negative SCCHN cell line JHU-028 transfected with either a negative control miRNA or miR-363.  (A) MTT 
assay of transfected cells grown in normal media (left) or serum-depleted media (right).  (B) Cell counting assay of 
transfected cells grown in normal media (left) or serum-depleted media (right). 
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Furthermore, an in vitro wound healing assay showed that miR-363 enhanced the ability 
of HPV-negative SCCHN cells to close the gap/lesion at a faster rate than in the presence of a 
control miRNA (Figure 18).  
 
 
 
Figure 18: MicroRNA-363 enhances the ability of HPV-negative SCCHN cells to close a gap/wound 
HPV-negative SCCHN cell line JHU-028 transfected with either a negative control miRNA or miR-363. (A) Wound 
healing assay pictures taken at 0 hours and 20 hours.  (B) Graph of wound healing assay at designated time points.  
The p value for cells expressing miR-363 compared to cells expressing a negative miRNA is indicated by ** (p < 
0.01). 
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4.3.4 MicroRNA-363 Increases Colony Formation by HPV-Negative SCCHN Cells 
Overexpression of miR-363 in HPV-negative SCCHN cell line PCI-30 showed an increase in the 
number of colonies formed by cells expressing miR-363 compared to cells expressing a negative 
control miRNA in a soft agar assay (Figure 19).  In addition, the colony size was significantly 
greater in cells expressing miR-363 compared to those expressing a negative control miRNA 
(Figure 19).  These results suggest that miR-363 may promote cell growth and colony formation.  
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Figure 19: MicroRNA-363 increases colony formation in HPV-negative SCCHN cells 
HPV-negative SCCHN cell line PCI-30 transfected with either a negative control miRNA or miR-363.  (A) Picture 
of a representative well of a six-well plate, showing colonies formed, including representative diameter.  (B) Graph 
representing the number of colonies formed per condition.  The p value for cells expressing miR-363 compared to 
cells expressing a negative miRNA is indicated by ** (p < 0.01). 
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4.4 DISCUSSION 
We have shown that miR-363 is overexpressed in HPV-positive SCCHN cell lines and tissue 
samples compared to HPV-negative SCCHN cell lines and tissues (Wald et al., 2011).  
Furthermore, expression of the HPV-16 E6 oncogene increases the expression of miR-363 while 
siRNA knockdown of HPV-16 E6 reduces miR-363 expression (Wald et al., 2011).  We sought 
to characterize the functional role of miR-363 in SCCHN. 
MiR-363 is part of the miR-106a~363 cluster of miRNAs, which is one of three miRNA 
clusters in the oncogenic miR-17~92 family of clusters (Ventura et al., 2008).  Several miRNAs 
in these clusters are upregulated in other cancers, including T-cell leukemia (Landais et al., 
2007), colon cancer (Bandres et al., 2006; Tsuchida et al., 2011; Volinia et al., 2006; Yu et al., 
2011), and lung cancer (Hayashita et al., 2005; Osada and Takahashi, 2011).  MiR-363, miR-25, 
and miR-92 all belong to the miR-17~92 family and have identical seed sequences (Ventura et 
al., 2008).  Since the seed sequence of a mature miRNA helps determine its target mRNA 
(Bartel, 2004), it is hypothesized that these three miRNAs could target similar (if not the same) 
genes (Ventura et al., 2008).  MiR-25 is overexpressed in bile duct, gastric, and ovarian cancers 
where it targets the TRAIL Death Receptor 4 (Razumilava et al., 2012), p57 (Kim et al., 2009), 
and BIM (Zhang et al., 2012), respectively.  Additionally, miR-92 levels are increased in colon 
cancer and small cell lung cancer where it targets BIM (Tsuchida et al., 2011) and RAB14 
(Kanzaki et al., 2011), respectively.  Moreover, in myeloid cells miR-92 targets p63 (Manni et 
al., 2009).  Because miR-363 has the same seed sequence as miR-25 and miR-92, and miR-25 
and miR-92 have been implicated in cell cycle regulation, it is possible that miR-363 has a 
similar function. 
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Since miRNAs can either target mRNA transcripts for degradation or promote their 
translational repression, a decrease in the levels of their target mRNA is not always observed 
(Eulalio et al., 2008).  We were successfully able to narrow the potential targets of miR-363 by 
utilizing spectral counting proteomics (Table 6), gene expression profiling data previously 
generated in our laboratory (Martinez et al., 2007), and computationally predicted miRNA target 
databases.  Myosin 1B (MYO1B) showed a significant decrease at the mRNA and protein levels 
when miR-363 was overexpressed (Figure 13), and was confirmed to be a direct target of miR-
363 by the luciferase assay (Figure 14).  Myosins are common motor proteins involved in many 
cellular processes, including cell motility (Edgar et al., 1996; Evangelista et al., 2000).  MiR-363 
overexpression caused by HPV-16 E6 in HPV-positive SCCHN cell lines results in a decrease in 
MYO1B expression (Figure 13) and reduces cell migration (Figure 15).  Additionally, when 
MYO1B levels were reduced via siRNA knockdown, cell migration also decreased (Figure 16).  
These data show that miR-363 expression causes a decrease in cell migration in SCCHN by 
reducing MYO1B expression. 
To test a more comprehensive role for miR-363 in SCCHN, we analyzed its possible 
roles via several functional assays.  Addition of exogenous miR-363 to HPV-negative SCCHN 
cells that do not express miR-363 caused an increase in cell proliferation, as measured by cell 
counting, MTT, wound healing, and colony formation assays (Figures 17-19).  The HPV E6 and 
E7 oncogenes are known to promote cell proliferation as well as viral replication (Moody and 
Laimins, 2010).  Overexpression of miR-363 by the HPV-16 E6 oncogene may be an additional 
mechanism by which HPVs could promote cell proliferation.  We were unable to significantly 
knock-down miR-363 levels in HPV-positive SCCHN cell lines by using either an antagomir to 
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miR-363 or by siRNA knockdown of E6 (data not shown).  Therefore, the direct effect of 
reducing miR-363 expression in HPV-positive SCCHN cell lines could not be tested. 
We also carried out colony formation assays in soft agar using the HPV-negative SCCHN 
cell line PCI-30.  The colony forming ability of these cells has not been previously characterized.  
We found that overexpression of miR-363 in this cell line increased both the number and size of 
the colonies (Figure 19).  This was particularly striking because in these cells, very few colonies 
were observed when a negative control miRNA was expressed but many colonies were seen in 
the presence of miR-363 (Figure 19).  Thus, our observation that HPV-negative SCCHN cells 
form larger colonies when expressing miR-363 compared to a negative control miRNA supports 
our results that miR-363 promotes the proliferative ability of SCCHN cells.  
The data presented in this study show that miR-363 targets MYO1B which reduces cell 
migration.  Furthermore, miR-363 increases proliferation and colony formation of HPV-negative 
SCCHN cells.  This data could give more insight and help lead to a better understanding of the 
differences between HPV-positive and HPV-negative SCCHN.  Based on our study, we envision 
that infection with HPV-16 causes overexpression of the E6 and E7 oncogenes and E6 
expression results in an increase in miR-363 levels.  High expression of miR-363 may then 
reduce MYO1B levels, thereby reducing the migratory ability of these cells.  Furthermore, high 
levels of miR-363 may also promote cellular proliferation and colony formation.  
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5.0  SUMMARY, CONCLUSION, AND FUTURE DIRECTIONS 
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5.1 GENERAL SUMMARY AND CONCLUSIONS 
High-risk HPV infection is associated with several cancers, including cervical, anogenital and a 
subset of head and neck cancer (De Vuyst et al., 2009; Frisch et al., 1997; Pascual et al., 2007; 
Tran et al., 2007b; Walboomers et al., 1999).  The number of HPV-positive SCCHN cases has 
been increasing in the past ten years, and the characteristics of HPV-positive and HPV-negative 
SCCHN are different, leading some to treat them as distinct tumor entities (Chaturvedi et al., 
2008; D'Souza et al., 2007).  The role of miRNAs in the regulation of gene expression has 
provided insights into the dysregulation of miRNA expression profiles in human diseases, 
including cancers (Esquela-Kerscher and Slack, 2006).  We hypothesized that overexpression of 
the E6 and E7 oncogenes in HPV-positive SCCHN would alter miRNA profiles in SCCHN 
differently than in HPV-negative SCCHN.  Differences between miRNA profiles in HPV-
positive and HPV-negative SCCHN would lead to specific alterations in the targets of these 
miRNAs, giving rise to the different characteristics observed for HPV-positive and HPV-
negative SCCHN.   
These studies are amongst the first to show a role for HPV in altering cellular miRNA 
profiles in SCCHN.  The miRNA microarray analysis showed dysregulation of several miRNAs 
in the HPV-positive SCCHN cell lines compared to the HPV-negative SCCHN cell lines.  
Several of these miRNAs were altered specifically in the presence of HPV-16 E6 and/or E7, 
including the upregulation of miR-363, and the downregulation of miR-181a, miR-218, and 
miR-29a.  Additionally, siRNA knockdown of HPV-16 E6 in HPV-positive SCCHN cell lines 
showed reduced expression of miR-363, indicating that miR-363 expression was dependent upon 
HPV-16 E6 expression (Wald et al., 2011).   
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We further showed that in addition to the HPV-positive SCCHN cell lines, miR-363 was 
also overexpressed in tissue samples from HPV-positive SCCHN patients from Western 
Pennsylvania compared to the HPV-negative SCCHN tissues.  These results suggest that miR-
363 overexpression may have clinical relevance.  Additionally, the characteristics of our SCCHN 
tissues were similar to a previously published study (Chaturvedi et al., 2008).  The tonsil and 
base of tongue had the highest rate of HPV-positivity, and represented 88% of HPV-positive 
SCCHN tissues in our cohort, while the HPV-negative SCCHN tumors were evenly distributed 
between the various head and neck sites.  Patients with HPV-positive SCCHN were about nine 
years younger than those with HPV-negative SCCHN, and a vast majority of the HPV-positive 
SCCHN tissues compared to only one-half of the HPV-negative SCCHN tissues were classified 
as T1 or T2 tumors. 
Since miRNAs act to repress their target mRNAs (Bartel, 2004), we utilized gene 
expression data, spectral counting proteomics, and computationally predicted miRNA target 
databases to show that miR-363 targets MYO1B in SCCHN.  Furthermore, high levels of miR-
363, and low levels of MYO1B reduced cell migration in SCCHN cells.  To further elucidate the 
role of miR-363 in SCCHN, we carried out several studies which suggested that miR-363 
increases proliferation and colony formation of SCCHN cells.  
It is not surprising that miRNA expression profiles are different in HPV-positive and 
HPV-negative SCCHN.  HPV alters miRNA profiles in HaCaT cells that were transfected with 
the HPV-11, -16, or -45 whole genomes (Dreher et al., 2011), as well as HaCaT cells transfected 
with only the HPV-16 E5 gene (Greco et al., 2011).  Although transfection with one gene or the 
entire HPV genome does not mimic natural HPV infection, it confirms that the HPV viral genes 
can alter cellular miRNA profiles.  There are many reports on dysregulated miRNAs in cervical 
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cancer (99% of which are caused by high-risk HPV) and head and neck cancer, but our studies 
are amongst the first to show that miRNAs are dysregulated differently in HPV-positive and 
HPV-negative SCCHN.   
5.2 FUTURE DIRECTIONS 
The data presented here show that miRNA profiles in HPV-positive and HPV-negative SCCHN 
are different.  Furthermore, miR-363 is overexpressed in HPV-positive SCCHN compared to 
HPV-negative SCCHN, targets MYO1B to reduce cellular migration, and increases cellular 
proliferation and colony formation.  Additional studies are necessary to further analyze the role 
of miRNAs in the development of HPV-associated SCCHN.  For example, identification of the 
mechanism by which the E6 oncogene of HPV-16 promotes the overexpression of miR-363 
would be of great interest.  The cellular functions and domains of HPV E6 are well 
characterized.  We have used three HPV-16 E6 mutants (F2V, L50G, and L110Q) that are 
defective in their interaction with specific cellular targets, but we were unable to identify a direct 
mechanism by which E6 regulates cellular miRNAs.  Future studies would include the use of 
additional E6 mutants to study the mechanism of upregulation of miR-363 by the E6 oncogene.  
MiR-363 is part of a cluster of miR-106a~363 miRNAs, however only miR-363 was 
found to be overexpressed in our studies.  A cluster of miRNAs is defined by the proximity to 
other miRNAs and can either have one promoter for the transcription of polycistronic miRNAs, 
or a miRNA cluster can have multiple promoters (Monteys et al., 2010; Ozsolak et al., 2008; 
Wang et al., 2009b).  The promoter(s) of the miR-106a~363 cluster are not known, and since 
only miR-363 is overexpressed in HPV-positive SCCHN, it is likely that either miR-363 has its 
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own promoter or it is processed differently from a polycistronic RNA than other miRNAs in the 
cluster.  Identifying the miR-363 (or cluster) promoter, and the mechanism of its upregulation in 
HPV-positive SCCHN should provide valuable insight into the development of this disease.  A 
previous report predicted the transcription start site for miR-363 (Ozsolak et al., 2008), and 
provides a good starting point for such studies.  The cloning of such regions into a promoter-less 
luciferase vector should lead to the identification of the miR-363 promoter.  Once a promoter 
region for miR-363 has been identified, chromatin immunoprecipitation (ChIP) assays could be 
done to investigate whether E6 (or one of its downstream targets) binds to the miR-363 
promoter.  The E6 protein could also be targeted to the miR-363 promoter through its interaction 
with a cellular transcription factor that acts at this promoter.  In addition, epigenetic mechanisms 
may also be involved in the regulation of miR-363 expression.  There have been previous reports 
demonstrating silencing of miRNAs by DNA methylation in oral cancer (Kozaki et al., 2008; 
Langevin et al., 2011).  In vitro analysis of SCCHN cells treated with 5-azacytidine which 
inhibits DNA methylation, or trichostatin A which inhibits histone deacetylation, may provide 
insight into the possible regulation of miR-363 by epigenetic mechanisms.   
Additionally, since we have shown that expression of HPV-16 E6 in primary human 
keratinocytes increases miR-363 levels (Figure 7), gene expression analysis of the E6-expressing 
keratinocytes may provide clues to cellular factors which may be involved in the upregulation of 
miR-363.  
Another direction for future experiments could involve the ability of miR-363 to induce 
or prevent tumor formation.  We have shown that HPV-negative SCCHN cells expressing 
exogenous miR-363 form more colonies (via soft agar assay, Figure 19).  This initial finding 
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could be further explored in animal model systems, which may give insight into the in vivo role 
of miR-363 in HPV-positive SCCHN. 
This dissertation details the role of one altered miRNA, miR-363, in HPV-positive 
SCCHN.  There were several other miRNAs whose levels were altered in HPV-positive 
compared to HPV-negative SCCHN cells that could be investigated for their role in the 
development of HPV-positive SCCHN as well as for diagnosis and developing new treatment 
approaches for SCCHN. 
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SUPPLEMENTARY TABLES 
Supplementary Table 1 Basal expression of miRNAs in HPV-16 positive SCCHN cell lines
Name Median 
hsa_miR_21 15166.0 
hsa_miR_16 9969.5 
hsa_miR_29a 9183.5 
hsa_miR_23b 5818.5 
hsa_miR_221 5180.5 
hsa_miR_24 5157.0 
hsa_miR_23a 4930.0 
hsa_let_7a 4129.5 
hsa_miR_31 4102.0 
hsa_miR_222 3579.5 
hsa_miR_30a_5p 2689.0 
hsa_miR_26a 2684.5 
hsa_miR_29b 2591.5 
hsa_miR_107 2116.5 
hsa_miR_15b 2051.5 
hsa_miR_103 2039.5 
hsa_miR_106a 2014.5 
hsa_miR_30d 1795.5 
hsa_miR_27b 1665.5 
hsa_let_7d 1655.0 
hsa_miR_93 1534.5 
hsa_miR_106b 1533.5 
hsa_miR_205 1515.5 
hsa_miR_125b 1407.5 
hsa_miR_100 1324.0 
hsa_miR_182 1264.0 
hsa_miR_17_5p 1250.5 
hsa_miR_130a 1176.0 
hsa_miR_30c 1086.0 
hsa_let_7c 1054.5 
hsa_miR_22 1054.0 
hsa_let_7i 1031.0 
hsa_miR_181a 991.0 
hsa_miR_200c 965.5 
hsa_let_7b 862.0 
hsa_miR_27a 856.0 
hsa_miR_25 842.5 
hsa_let_7e 826.0 
hsa_let_7f 807.0 
hsa_miR_181b 791.0 
hsa_miR_99a 791.0 
hsa_miR_19b 719.5 
hsa_miR_20a 682.5 
hsa_miR_15a 598.0 
hsa_let_7g 592.5 
hsa_miR_20b 562.5 
hsa_miR_30b 560.0 
hsa_miR_155 540.5 
hsa_miR_191 508.5 
hsa_miR_210 405.5 
hsa_miR_30e_5p 394.0 
hsa_miR_200b 324.0 
hsa_miR_125a 318.5 
hsa_miR_361 313.0 
hsa_miR_320 278.0 
hsa_miR_203 207.5 
hsa_miR_138 202.5 
hsa_miR_185 183.0 
hsa_miR_130b 170.0 
hsa_miR_181d 138.0 
hsa_miR_7 123.0 
hsa_miR_96 122.0 
hsa_miR_92 121.5 
hsa_miR_422b 110.5 
hsa_miR_99b 107.5 
hsa_miR_18a 98.0 
hsa_miR_494 97.0 
hsa_miR_193b 91.5 
hsa_miR_224 85.5 
hsa_miR_151 82.5 
hsa_miR_152 80.5 
hsa_miR_128a 76.0 
hsa_miR_196a 69.0 
hsa_miR_200a 68.5 
hsa_miR_128b 67.0 
hsa_miR_423 63.5 
hsa_miR_136 63.0 
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hsa_miR_26b 58.5 
hsa_miR_29c 55.5 
hsa_miR_28 55.0 
hsa_miR_342 50.0 
hsa_miR_193a 43.0 
hsa_miR_10a 42.5 
hsa_miR_18b 37.0 
hsa_miR_183 36.0 
hsa_miR_30a_3p 35.0 
hsa_miR_301 34.5 
hsa_miR_146b 31.0 
hsa_miR_362 26.5 
hsa_miR_146a 25.0 
hsa_miR_98 23.5 
hsa_miR_196b 22.5 
hsa_miR_218 19.0 
hsa_miR_339 18.5 
hsa_miR_189 18.0 
hsa_miR_452 17.5 
hsa_miR_324_3p 17.0 
hsa_miR_142_5p 16.5 
hsa_miR_503 16.0 
hsa_miR_194 15.5 
hsa_miR_491 15.5 
hsa_miR_455 14.5 
hsa_miR_19a 14.0 
hsa_miR_17_3p 12.5 
hsa_miR_195 11.5 
hsa_miR_141 11.0 
hsa_miR_30e_3p 10.0 
hsa_miR_148a 9.0 
hsa_miR_186 9.0 
hsa_miR_345 8.0 
hsa_miR_500 8.0 
hsa_miR_335 7.0 
hsa_miR_126 6.5 
hsa_miR_143 6.5 
hsa_miR_213 6.5 
hsa_miR_331 5.0 
hsa_miR_424 5.0 
hsa_miR_198 4.5 
hsa_miR_181c 4.0 
hsa_miR_9_AS 3.5 
hsa_miR_192 2.5 
hsa_miR_363_AS 2.5 
hsa_miR_422a 2.5 
hsa_miR_429 2.5 
hsa_miR_145 1.5 
hsa_miR_485_5p 1.5 
hsa_miR_489 1.0 
hsa_miR_18a_AS 0.5 
hsa_miR_513 0.5 
hsa_miR_1 0.0 
hsa_miR_101 0.0 
hsa_miR_105 0.0 
hsa_miR_10b 0.0 
hsa_miR_122a 0.0 
hsa_miR_124a 0.0 
hsa_miR_126_AS 0.0 
hsa_miR_127 0.0 
hsa_miR_129 0.0 
hsa_miR_132 0.0 
hsa_miR_133a 0.0 
hsa_miR_133b 0.0 
hsa_miR_134 0.0 
hsa_miR_135a 0.0 
hsa_miR_135b 0.0 
hsa_miR_137 0.0 
hsa_miR_139 0.0 
hsa_miR_140 0.0 
hsa_miR_142_3p 0.0 
hsa_miR_144 0.0 
hsa_miR_147 0.0 
hsa_miR_148b 0.0 
hsa_miR_149 0.0 
hsa_miR_150 0.0 
hsa_miR_153 0.0 
hsa_miR_154 0.0 
hsa_miR_154_AS 0.0 
hsa_miR_182_AS 0.0 
hsa_miR_184 0.0 
hsa_miR_187 0.0 
hsa_miR_188 0.0 
hsa_miR_190 0.0 
hsa_miR_191_AS 0.0 
hsa_miR_197 0.0 
hsa_miR_199a 0.0 
hsa_miR_199a_AS 0.0 
hsa_miR_199b 0.0 
hsa_miR_200a_AS 0.0 
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hsa_miR_202 0.0 
hsa_miR_202_AS 0.0 
hsa_miR_204 0.0 
hsa_miR_206 0.0 
hsa_miR_208 0.0 
hsa_miR_211 0.0 
hsa_miR_212 0.0 
hsa_miR_214 0.0 
hsa_miR_215 0.0 
hsa_miR_216 0.0 
hsa_miR_217 0.0 
hsa_miR_219 0.0 
hsa_miR_220 0.0 
hsa_miR_223 0.0 
hsa_miR_296 0.0 
hsa_miR_299_3p 0.0 
hsa_miR_299_5p 0.0 
hsa_miR_302a 0.0 
hsa_miR_302a_AS 0.0 
hsa_miR_302b 0.0 
hsa_miR_302b_AS 0.0 
hsa_miR_302c 0.0 
hsa_miR_302c_AS 0.0 
hsa_miR_302d 0.0 
hsa_miR_32 0.0 
hsa_miR_323 0.0 
hsa_miR_324_5p 0.0 
hsa_miR_325 0.0 
hsa_miR_326 0.0 
hsa_miR_328 0.0 
hsa_miR_329 0.0 
hsa_miR_33 0.0 
hsa_miR_330 0.0 
hsa_miR_337 0.0 
hsa_miR_338 0.0 
hsa_miR_340 0.0 
hsa_miR_346 0.0 
hsa_miR_34a 0.0 
hsa_miR_34b 0.0 
hsa_miR_34c 0.0 
hsa_miR_363 0.0 
hsa_miR_365 0.0 
hsa_miR_367 0.0 
hsa_miR_368 0.0 
hsa_miR_369_3p 0.0 
hsa_miR_369_5p 0.0 
hsa_miR_370 0.0 
hsa_miR_371 0.0 
hsa_miR_372 0.0 
hsa_miR_373 0.0 
hsa_miR_373_AS 0.0 
hsa_miR_374 0.0 
hsa_miR_375 0.0 
hsa_miR_376a 0.0 
hsa_miR_376a_AS 0.0 
hsa_miR_376b 0.0 
hsa_miR_377 0.0 
hsa_miR_378 0.0 
hsa_miR_379 0.0 
hsa_miR_380_3p 0.0 
hsa_miR_380_5p 0.0 
hsa_miR_381 0.0 
hsa_miR_382 0.0 
hsa_miR_383 0.0 
hsa_miR_384 0.0 
hsa_miR_409_3p 0.0 
hsa_miR_409_5p 0.0 
hsa_miR_410 0.0 
hsa_miR_412 0.0 
hsa_miR_425 0.0 
hsa_miR_431 0.0 
hsa_miR_432 0.0 
hsa_miR_432_AS 0.0 
hsa_miR_433 0.0 
hsa_miR_448 0.0 
hsa_miR_449 0.0 
hsa_miR_450 0.0 
hsa_miR_451 0.0 
hsa_miR_452_AS 0.0 
hsa_miR_453 0.0 
hsa_miR_483 0.0 
hsa_miR_484 0.0 
hsa_miR_485_3p 0.0 
hsa_miR_486 0.0 
hsa_miR_487a 0.0 
hsa_miR_487b 0.0 
hsa_miR_488 0.0 
hsa_miR_490 0.0 
hsa_miR_492 0.0 
hsa_miR_493_3p 0.0 
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hsa_miR_493_5p 0.0 
hsa_miR_495 0.0 
hsa_miR_496 0.0 
hsa_miR_497 0.0 
hsa_miR_498 0.0 
hsa_miR_499 0.0 
hsa_miR_501 0.0 
hsa_miR_502 0.0 
hsa_miR_504 0.0 
hsa_miR_505 0.0 
hsa_miR_506 0.0 
hsa_miR_507 0.0 
hsa_miR_508 0.0 
hsa_miR_509 0.0 
hsa_miR_510 0.0 
hsa_miR_511 0.0 
hsa_miR_512_3p 0.0 
hsa_miR_512_5p 0.0 
hsa_miR_514 0.0 
hsa_miR_515_3p 0.0 
hsa_miR_515_5p 0.0 
hsa_miR_516_3p 0.0 
hsa_miR_516_5p 0.0 
hsa_miR_517_AS 0.0 
hsa_miR_517a 0.0 
hsa_miR_517b 0.0 
hsa_miR_517c 0.0 
hsa_miR_518a 0.0 
hsa_miR_518a_2_AS 0.0 
hsa_miR_518b 0.0 
hsa_miR_518c 0.0 
hsa_miR_518c_AS 0.0 
hsa_miR_518d 0.0 
hsa_miR_518e 0.0 
hsa_miR_518f 0.0 
hsa_miR_518f_AS 0.0 
hsa_miR_519a 0.0 
hsa_miR_519b 0.0 
hsa_miR_519c 0.0 
hsa_miR_519d 0.0 
hsa_miR_519e 0.0 
hsa_miR_519e_AS 0.0 
hsa_miR_520a 0.0 
hsa_miR_520a_AS 0.0 
hsa_miR_520b 0.0 
hsa_miR_520c 0.0 
hsa_miR_520d 0.0 
hsa_miR_520d_AS 0.0 
hsa_miR_520e 0.0 
hsa_miR_520f 0.0 
hsa_miR_520g 0.0 
hsa_miR_520h 0.0 
hsa_miR_521 0.0 
hsa_miR_522 0.0 
hsa_miR_523 0.0 
hsa_miR_524 0.0 
hsa_miR_524_AS 0.0 
hsa_miR_525 0.0 
hsa_miR_525_AS 0.0 
hsa_miR_526a 0.0 
hsa_miR_526b 0.0 
hsa_miR_526b_AS 0.0 
hsa_miR_526c 0.0 
hsa_miR_527 0.0 
hsa_miR_539 0.0 
hsa_miR_542_3p 0.0 
hsa_miR_542_5p 0.0 
hsa_miR_544 0.0 
hsa_miR_545 0.0 
hsa_miR_9 0.0 
hsa_miR_95 0.0 
 
The basal expression of miRNAs in the HPV-negative cell lines PCI-13 and PCI-30 was 
identified using miRNA microarrays. We obtained the median fluorescent intensity for each 
miRNA, and miRNAs having values of zero in at least four of their corresponding spots (4 spots 
per array and two arrays per sample) were considered to be non-expressing. 
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Supplementary Table 2 Basal expression of miRNAs in HPV-16 positive SCCHN cell lines 
Name Median 
hsa_miR_205 25541.5 
hsa_miR_16 22308.0 
hsa_miR_24 7394.0 
hsa_miR_23b 6441.5 
hsa_miR_141 6103.0 
hsa_miR_26a 5640.0 
hsa_miR_21 5434.0 
hsa_let_7a 5364.5 
hsa_miR_23a 4327.0 
hsa_miR_27b 4024.0 
hsa_miR_203 3831.5 
hsa_miR_200b 3692.0 
hsa_miR_106a 3677.0 
hsa_miR_106b 3634.0 
hsa_miR_107 3458.0 
hsa_miR_93 3143.5 
hsa_let_7i 3062.0 
hsa_miR_15b 2664.5 
hsa_miR_17_5p 2634.0 
hsa_miR_200c 2559.5 
hsa_let_7b 2537.5 
hsa_let_7c 2512.5 
hsa_let_7d 2493.5 
hsa_miR_103 2413.0 
hsa_miR_19b 2231.5 
hsa_miR_200a 2214.0 
hsa_miR_25 2114.0 
hsa_miR_31 1904.5 
hsa_miR_99a 1839.5 
hsa_miR_30a_5p 1630.5 
hsa_miR_130a 1534.5 
hsa_let_7f 1483.5 
hsa_miR_27a 1469.0 
hsa_miR_15a 1458.5 
hsa_miR_30d 1436.0 
hsa_miR_30b 1379.0 
hsa_miR_221 1369.5 
hsa_miR_125b 1243.0 
hsa_miR_182 1236.5 
hsa_miR_20b 1213.0 
hsa_miR_34a 1188.0 
hsa_miR_29a 1083.0 
hsa_miR_22 1010.5 
hsa_let_7g 1005.5 
hsa_miR_20a 981.0 
hsa_miR_494 944.5 
hsa_miR_30e_5p 933.0 
hsa_miR_191 814.0 
hsa_let_7e 802.5 
hsa_miR_30c 765.5 
hsa_miR_222 744.0 
hsa_miR_422b 678.0 
hsa_miR_361 659.5 
hsa_miR_363 636.5 
hsa_miR_125a 572.0 
hsa_miR_92 517.0 
hsa_miR_320 471.5 
hsa_miR_18a 441.0 
hsa_miR_210 423.0 
hsa_miR_195 414.5 
hsa_miR_99b 377.5 
hsa_miR_148a 282.5 
hsa_miR_342 274.5 
hsa_miR_130b 273.0 
hsa_miR_151 269.0 
hsa_miR_224 259.0 
hsa_miR_18b 245.5 
hsa_miR_128a 226.0 
hsa_miR_152 213.0 
hsa_miR_96 183.5 
hsa_miR_128b 182.5 
hsa_miR_100 169.0 
hsa_miR_423 156.0 
hsa_miR_7 151.5 
hsa_miR_19a 146.0 
hsa_miR_29b 145.0 
hsa_miR_183 140.5 
hsa_miR_185 139.5 
hsa_miR_26b 125.5 
hsa_miR_28 114.0 
hsa_miR_301 111.0 
hsa_miR_429 99.0 
hsa_miR_29c 98.0 
hsa_miR_193a 84.0 
hsa_miR_17_3p 83.5 
hsa_miR_339 79.5 
hsa_miR_362 78.5 
 97 
hsa_miR_138 78.0 
hsa_miR_196a 72.5 
hsa_miR_189 63.0 
hsa_miR_98 53.0 
hsa_miR_324_3p 42.0 
hsa_miR_335 42.0 
hsa_miR_422a 41.5 
hsa_miR_331 38.0 
hsa_miR_186 35.5 
hsa_miR_491 35.5 
hsa_miR_136 32.5 
hsa_miR_194 31.5 
hsa_miR_30e_3p 30.5 
hsa_miR_345 29.5 
hsa_miR_452 29.0 
hsa_miR_181b 26.5 
hsa_miR_192 26.0 
hsa_miR_484 23.5 
hsa_miR_363_AS 23.0 
hsa_miR_503 22.5 
hsa_miR_196b 21.5 
hsa_miR_497 21.5 
hsa_miR_193b 20.0 
hsa_miR_378 19.0 
hsa_miR_149 18.5 
hsa_miR_511 18.5 
hsa_miR_379 18.0 
hsa_miR_202 17.5 
hsa_miR_146b 16.5 
hsa_miR_500 16.5 
hsa_miR_198 16.0 
hsa_miR_132 15.5 
hsa_miR_513 15.5 
hsa_miR_370 15.0 
hsa_miR_432 15.0 
hsa_miR_521 14.5 
hsa_miR_148b 14.0 
hsa_miR_18a_AS 14.0 
hsa_miR_197 13.0 
hsa_miR_200a_AS 13.0 
hsa_miR_453 13.0 
hsa_miR_181a 12.0 
hsa_miR_101 11.5 
hsa_miR_30a_3p 11.5 
hsa_miR_33 11.5 
hsa_miR_126 9.5 
hsa_miR_188 9.5 
hsa_miR_425 9.5 
hsa_miR_330 8.5 
hsa_miR_213 8.0 
hsa_miR_373_AS 8.0 
hsa_miR_9_AS 8.0 
hsa_miR_374 7.5 
hsa_miR_485_5p 7.5 
hsa_miR_505 7.0 
hsa_miR_542_5p 7.0 
hsa_miR_181d 6.5 
hsa_miR_518c_AS 6.0 
hsa_miR_155 5.5 
hsa_miR_182_AS 5.5 
hsa_miR_324_5p 5.5 
hsa_miR_409_5p 5.5 
hsa_miR_122a 5.0 
hsa_miR_181c 5.0 
hsa_miR_184 5.0 
hsa_miR_302c_AS 5.0 
hsa_miR_346 5.0 
hsa_miR_34b 5.0 
hsa_miR_492 4.5 
hsa_miR_299_3p 4.0 
hsa_miR_129 3.5 
hsa_miR_142_3p 3.5 
hsa_miR_365 3.5 
hsa_miR_483 3.5 
hsa_miR_519e_AS 3.5 
hsa_miR_10a 3.0 
hsa_miR_206 3.0 
hsa_miR_212 3.0 
hsa_miR_424 3.0 
hsa_miR_134 2.5 
hsa_miR_140 2.5 
hsa_miR_368 2.5 
hsa_miR_373 2.5 
hsa_miR_450 2.5 
hsa_miR_452_AS 2.5 
hsa_miR_455 2.5 
hsa_miR_517a 2.5 
hsa_miR_519d 2.5 
hsa_miR_544 2.5 
hsa_miR_10b 2.0 
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hsa_miR_127 2.0 
hsa_miR_143 2.0 
hsa_miR_328 2.0 
hsa_miR_499 2.0 
hsa_miR_518a_2_AS 2.0 
hsa_miR_145 1.5 
hsa_miR_187 1.5 
hsa_miR_199a 1.5 
hsa_miR_220 1.5 
hsa_miR_371 1.5 
hsa_miR_381 1.5 
hsa_miR_431 1.5 
hsa_miR_485_3p 1.5 
hsa_miR_493_3p 1.5 
hsa_miR_495 1.5 
hsa_miR_501 1.5 
hsa_miR_519c 1.5 
hsa_miR_9 1.5 
hsa_miR_32 1.0 
hsa_miR_486 1.0 
hsa_miR_487a 1.0 
hsa_miR_489 1.0 
hsa_miR_502 1.0 
hsa_miR_515_5p 1.0 
hsa_miR_520d 1.0 
hsa_miR_520d_AS 1.0 
hsa_miR_526b 1.0 
hsa_miR_527 1.0 
hsa_miR_542_3p 1.0 
hsa_miR_133b 0.5 
hsa_miR_146a 0.5 
hsa_miR_199b 0.5 
hsa_miR_380_3p 0.5 
hsa_miR_449 0.5 
hsa_miR_487b 0.5 
hsa_miR_510 0.5 
hsa_miR_517b 0.5 
hsa_miR_518f 0.5 
hsa_miR_525 0.5 
hsa_miR_1 0.0 
hsa_miR_105 0.0 
hsa_miR_124a 0.0 
hsa_miR_126_AS 0.0 
hsa_miR_133a 0.0 
hsa_miR_135a 0.0 
hsa_miR_135b 0.0 
hsa_miR_137 0.0 
hsa_miR_139 0.0 
hsa_miR_142_5p 0.0 
hsa_miR_144 0.0 
hsa_miR_147 0.0 
hsa_miR_150 0.0 
hsa_miR_153 0.0 
hsa_miR_154 0.0 
hsa_miR_154_AS 0.0 
hsa_miR_190 0.0 
hsa_miR_191_AS 0.0 
hsa_miR_199a_AS 0.0 
hsa_miR_202_AS 0.0 
hsa_miR_204 0.0 
hsa_miR_208 0.0 
hsa_miR_211 0.0 
hsa_miR_214 0.0 
hsa_miR_215 0.0 
hsa_miR_216 0.0 
hsa_miR_217 0.0 
hsa_miR_218 0.0 
hsa_miR_219 0.0 
hsa_miR_223 0.0 
hsa_miR_296 0.0 
hsa_miR_299_5p 0.0 
hsa_miR_302a 0.0 
hsa_miR_302a_AS 0.0 
hsa_miR_302b 0.0 
hsa_miR_302b_AS 0.0 
hsa_miR_302c 0.0 
hsa_miR_302d 0.0 
hsa_miR_323 0.0 
hsa_miR_325 0.0 
hsa_miR_326 0.0 
hsa_miR_329 0.0 
hsa_miR_337 0.0 
hsa_miR_338 0.0 
hsa_miR_340 0.0 
hsa_miR_34c 0.0 
hsa_miR_367 0.0 
hsa_miR_369_3p 0.0 
hsa_miR_369_5p 0.0 
hsa_miR_372 0.0 
hsa_miR_375 0.0 
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hsa_miR_376a 0.0 
hsa_miR_376a_AS 0.0 
hsa_miR_376b 0.0 
hsa_miR_377 0.0 
hsa_miR_380_5p 0.0 
hsa_miR_382 0.0 
hsa_miR_383 0.0 
hsa_miR_384 0.0 
hsa_miR_409_3p 0.0 
hsa_miR_410 0.0 
hsa_miR_412 0.0 
hsa_miR_432_AS 0.0 
hsa_miR_433 0.0 
hsa_miR_448 0.0 
hsa_miR_451 0.0 
hsa_miR_488 0.0 
hsa_miR_490 0.0 
hsa_miR_493_5p 0.0 
hsa_miR_496 0.0 
hsa_miR_498 0.0 
hsa_miR_504 0.0 
hsa_miR_506 0.0 
hsa_miR_507 0.0 
hsa_miR_508 0.0 
hsa_miR_509 0.0 
hsa_miR_512_3p 0.0 
hsa_miR_512_5p 0.0 
hsa_miR_514 0.0 
hsa_miR_515_3p 0.0 
hsa_miR_516_3p 0.0 
hsa_miR_516_5p 0.0 
hsa_miR_517_AS 0.0 
hsa_miR_517c 0.0 
hsa_miR_518a 0.0 
hsa_miR_518b 0.0 
hsa_miR_518c 0.0 
hsa_miR_518d 0.0 
hsa_miR_518e 0.0 
hsa_miR_518f_AS 0.0 
hsa_miR_519a 0.0 
hsa_miR_519b 0.0 
hsa_miR_519e 0.0 
hsa_miR_520a 0.0 
hsa_miR_520a_AS 0.0 
hsa_miR_520b 0.0 
hsa_miR_520c 0.0 
hsa_miR_520e 0.0 
hsa_miR_520f 0.0 
hsa_miR_520g 0.0 
hsa_miR_520h 0.0 
hsa_miR_522 0.0 
hsa_miR_523 0.0 
hsa_miR_524 0.0 
hsa_miR_524_AS 0.0 
hsa_miR_525_AS 0.0 
hsa_miR_526a 0.0 
hsa_miR_526b_AS 0.0 
hsa_miR_526c 0.0 
hsa_miR_539 0.0 
hsa_miR_545 0.0 
hsa_miR_95 0.0 
 
The basal expression of miRNAs in the HPV-16 positive cell lines UD-SCC-2 and 
UPCI:SCC90 was identified using miRNA microarrays. We obtained the median fluorescent 
intensity for each miRNA, and miRNAs having values of zero in at least four of their 
corresponding spots (4 spots per array and two arrays per sample) were considered to be non-
expressing. 
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Supplementary Table 3 MiRNAs Differentially Expressed in HPV-16-positive SCCHN cell 
line UD-SCC-2 compared to HPV-negative SCCHN cell line PCI-13 
 
MiRNA Fold Change 
  
Underexpressed  
  
hsa_miR_181a -13.72 
hsa_miR_181b -13.37 
miR, microRNA; hsa, human; The q-values of all miRNAs were 0.  
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Supplementary Table 4 MiRNAs Differentially Expressed in HPV-16-positive SCCHN cell 
line UD-SCC-2 compared to HPV-negative SCCHN cell line PCI-30 
 
MiRNA Fold Change 
  
Overexpressed  
  
hsa_miR_205 31.66 
hsa_miR_141 14.18 
hsa_miR_200c 11.39 
hsa_miR_34a 8.60 
hsa_miR_200b 7.69 
hsa_miR_363 4.85 
miR, microRNA; hsa, human; The q-values of all miRNAs were 0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
Supplementary Table 5 MiRNAs Differentially Expressed in HPV-16-positive SCCHN cell 
line UPCI:SCC90 compared to HPV-negative SCCHN cell line PCI-13 
 
MiRNA Fold Change 
  
Overexpressed  
  
hsa_miR_148a 5.56 
hsa_miR_363 5.47 
hsa_miR_186 4.69 
hsa_miR_101 3.54 
  
Underexpressed 
  
hsa_miR_155 -11.36 
hsa_miR_181a -5.63 
ambi_miR_13143 -5.43 
miR, microRNA; hsa, human; ambi, Ambion predicted; The q-values of all miRNAs were 0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
Supplementary Table 6 MiRNAs Differentially Expressed in HPV-16-positive SCCHN cell 
line UPCI:SCC90 compared to HPV-negative SCCHN cell line PCI-30 
 
MiRNA Fold Change 
  
Overexpressed  
  
hsa_miR_205 22.92 
hsa_miR_203 15.85 
hsa_miR_141 15.34 
hsa_miR_200c 11.47 
hsa_miR_34a 10.50 
hsa_miR_200b 9.47 
hsa_miR_200a 7.79 
hsa_miR_429 6.29 
hsa_miR_363 5.41 
hsa_miR_200a_AS 2.68 
miR, microRNA; hsa, human; The q-values of all miRNAs were 0.  
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